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Abstract
Background: Limited “real-world” evidence exists supporting insulin pump therapy (IPT)
benefits in adults with type 1 diabetes mellitus (T1DM).
Methods: A retrospective matched cohort study compared the change in glycated
hemoglobin (A1C) and incidence of adverse events before and after IPT start in adults
with T1DM at St. Joseph’s Healthcare in London, Ontario started on IPT between
September 2008 – August 2011 to those of a matched control cohort. Paired t-tests,
McNemar’s test and negative binomial regression were used.
Results: 174 matched pairs were included. At 1 year, glycaemic control significantly
improved in IPT users but not in controls—the mean paired difference in A1C change
was -0.3% (p=0.041, n=133 pairs)—and severe hypoglycaemia was lower in IPT than
controls (p=0.016).
Conclusions: Provincially-funded IPT in adults with T1DM was associated with clinically
significant improvement in glycaemic control and severe hypoglycaemia, providing “realworld” evidence supporting continued IPT funding in adults with T1DM.
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Chapter 1: Introduction
1.1 Overview and Statement of the Problem
Diabetes mellitus is a common metabolic disorder characterized by chronic
hyperglycaemia, and can be broadly classified by etiology into Type 1 and Type 2. Type 1
diabetes mellitus (T1DM) is a result of insulin deficiency due to pancreatic beta-cell
destruction. It is most commonly due to an autoimmune process and requires daily
insulin treatment. In 2013, it was estimated that ~ 381 million people worldwide,
including ~2.6 million people in Canada, have diabetes mellitus, of which 5-15% have
T1DM.1 The prevalence of T1DM, and of diabetes mellitus overall, is increasing.1
Insulin is the mainstay of treatment in T1DM, and the goal of insulin treatment is to
achieve blood glucose levels as close to normal levels as safely as possible. Strict
glycaemic control has been shown to decrease microvascular and neuropathic
complications, and also potentially reduce macrovascular complications, in patients with
T1DM. However, the benefits of strict glycaemic control must be balanced against the
risk of hypoglycaemia.
Intensive insulin treatment is the standard of care in T1DM, and it can be delivered
through use of insulin pump therapy (IPT) or a multiple daily insulin injection (MDI)
regimen.2 Insulin pump therapy is the use of a small, portable external pump attached to
a subcutaneous catheter to deliver a continuous basal infusion of insulin throughout the
day, as well as intermittent bolus insulin doses for meals. An MDI (or “basal-bolus”)
regimen is the use of injections of long- or intermediate-acting insulin once or twice
daily combined with injections of rapid- or short-acting insulin with each meal.
Meta-analyses of randomized controlled trials comparing IPT to MDI regimens in
different patient populations have shown that IPT improves glycaemic control. 3-11
However, the evidence is less clear regarding the benefit of IPT in improving other
clinically relevant outcomes, such as severe hypoglycaemic events and quality of life,
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and it is not known whether IPT ultimately reduces the risk of glycaemic-responsive
complications. Further, the relevance of these results to the “real-world” is not clear.
A major barrier to IPT is the financial burden associated with its use—the average price
of an insulin pump is ~$7,000.00 CAD, and the average cost of pump-associated supplies
is ~$250.00 CAD per month,12 which may be prohibitive to those without access to
private insurance coverage. In September 2008, the Ontario Ministry of Health and Long
Term Care (MOHLTC) began funding of IPT for eligible adults with T1DM through the
Assistive Devices Program (ADP), and, until recently, Ontario was the only province in
Canada to provide funding for IPT for adults.
As a tertiary care referral centre for Southwestern Ontario, St. Joseph’s Health Care
(SJHC), London provides a regional resource for care of T1DM. Patients with T1DM are
seen at the Diabetes Clinics at St. Joseph’s Hospital and the Primary Care Diabetes
Support Program (PCDSP) at the affiliated St. Joseph’s Family Medical Centre. Out of 71
ADP IPT provider sites for adults in Ontario, SJHC is one of the largest, and is also the
main ADP IPT provider site within the South West Local Health Integration Network.
Therefore, our patient population may be considered representative of adults with
T1DM province-wide, and thus the Diabetes Clinics of SJHC provide a “real-world”
setting in which the effectiveness of ADP-funded IPT can be closely examined. Since
2011, the Diabetes Clinics of SJHC have used WebDR, an electronic medical record (EMR)
system, for routine clinical care.
To date, the impact of ADP-funded IPT on glycaemic control in adults with T1DM in
Ontario has not previously been assessed. This study was the first to evaluate this issue.
In addition, this study was the first use of WebDR for research, and demonstrated its
utility as a comprehensive researchable database.
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1.2 Thesis Objectives
The purpose of this study was to describe the IPT experiences of adult patients with
T1DM under routine clinical care in the Diabetes Clinics at SJHC in London, Ontario, and
to assess the clinical impact of IPT funded through the Ontario MOHLTC ADP.
The main research question was:
Does ADP-funded IPT improve glycaemic control and reduce adverse outcomes at 1
year in adults with T1DM followed by the Diabetes Clinics at SJHC?
To answer this question, the primary objectives were as follows:
Objective 1: To establish a cohort of adults with T1DM who started on IPT from
September 1, 2008 – August 31, 2011, using a regional diabetes-specific EMR database,
for future studies in T1DM.
Objective 2: To describe the demographic and clinical characteristics of this cohort.
Objective 3: To compare the glycaemic control of this cohort at 1 year after IPT initiation
to that of a matched cohort of adults with T1DM not on IPT.
Objective 4: To compare the frequency of adverse DM-related events in this cohort at 1
year after IPT initiation, to that of the matched non-IPT cohort.
The secondary objective of this study was to test the validity of WebDR, the EMR in use
at the Diabetes Clinics of SJHC, as a researchable database.
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Chapter 2: Diabetes Mellitus
2.1 Definition and Types of Diabetes Mellitus
Diabetes mellitus is a common metabolic disorder characterized by chronic
hyperglycaemia due to inadequate insulin secretion, inadequate insulin action, or both.2
Diabetes mellitus can be broadly classified by etiology into Type 1 (T1DM) and Type 2
(T2DM). T1DM is most commonly due to autoimmune destruction of the pancreatic
beta-cells, i.e. Type 1A diabetes (which also includes LADA - latent autoimmune diabetes
in adults), but occasionally, non-immune-mediated beta-cell destruction can occur, i.e.
“idiopathic” or Type 1B diabetes.2,13 Both the 1A and 1B subtypes result in insulin
deficiency and hyperglycaemia which, if left untreated, causes serious acute and chronic
consequences.

2.2 Epidemiology of Type 1 Diabetes Mellitus
In 2013, the worldwide prevalence of all diabetes (both T1DM and T2DM) was estimated
to be 8.4% or ~381 million people, while the prevalence of all diabetes in Canada was
10.2% or ~2.6 million people.1 Since T1DM accounts for 5-15% of all cases of diabetes, it
can be estimated that there are approximately 38.1 million people worldwide and
260,000 people in Canada with T1DM.
The worldwide incidence of T1DM has marked geographic variation, with age-adjusted
incidence rates ranging from 0.1 per 100,000 per year in China and Venezuela to 40.9
per 100,000 per year in Finland.14 Moreover, the incidence of T1DM is increasing yearly,
with an overall worldwide increase of 3% per year among children under the age of
fourteen.1
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It is difficult to estimate the exact prevalence and incidence of T1DM in adults in
Ontario, as statistics from the Canadian National Diabetes Surveillance System (NDSS)
are based upon population-based administrative data which do not distinguish between
T1DM and T2DM. However, given that T1DM accounts for 5-15% of all cases of diabetes,
it is assumed that the NDSS statistics reflect this same proportion. Similar to the trend
worldwide, the most recent NDSS report also showed increasing prevalence and
incidence of diabetes in Canada from 1998/99 – 2008/09, with Ontario having the third
highest age-standardized prevalence and second highest age-standardized incidence
nationwide.15

2.3 Pathogenesis of Type 1 Diabetes Mellitus
Type 1 diabetes mellitus is characterized by pancreatic beta-cell destruction by either
immune-mediated (type 1A) or idiopathic/non-immune-mediated processes (type 1B).
The exact cause of T1DM is not known, though in the case of immune-mediated (type
1A) diabetes, it is believed that one or more environmental factors may trigger
development in genetically susceptible people.16
The major genetic determinant of the risk of T1DM is contained within the HLA
genotype, with DR3-DQ2/DR4-DQ8 being the highest risk genotype.17 Other genes
implicated in the susceptibility to T1DM are the insulin gene18 and the gene for PTPN22,
a lymphoid-specific phosphatase involved in T-cell receptor signaling.19
Proposed environmental triggers for the development of T1DM include viral infections,
such as congenital rubella,20 enterovirus,21 and rotavirus,22 and dietary factors such as
cow’s milk23 and early exposure to cereal in infancy.24
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2.4 Management of Type 1 Diabetes Mellitus
The Canadian Diabetes Association (CDA) recommends that management of T1DM be
focused around the individual patient, with support from a multi-disciplinary team of
diabetes experts.2 Important facets of T1DM care include monitoring blood glucose
levels, physical activity, appropriate nutrition, and insulin administration. The goal of
T1DM management is the prevention of acute and chronic complications in order to
reduce morbidity and premature mortality.
The main laboratory parameter used to monitor glycaemic control in diabetes is the
glycated hemoglobin (A1C). Hemoglobin is a protein in red blood cells that is essential
for oxygen transport. Newly formed red blood cells contain hemoglobin that does not
have any glucose attached—however, as red blood cells are permeable to glucose,
glucose in the blood irreversibly binds to hemoglobin, forming glycated hemoglobin, at a
rate dependent on the blood glucose concentration. Given that the average life span of
a red blood cell is ~120 days, the A1C reflects the mean plasma glucose over the past 3-4
months. However, it is a weighted average, with blood glucose levels in the preceding 30
days contributing ~50% of the result, and levels from 90-120 days prior contributing
~10% of the result. 25 In Canada, A1C is reported in National Glycohemoglobin
Standardization Program units, which use a percent.2 Therefore, A1C can be expressed
as a decimal or a percent (i.e. an A1C of 0.070 = 7.0%).
The Diabetes Control and Complications Trial (DCCT) was a landmark multicentre
randomized controlled trial in 1,441 patients with T1DM which compared the effect of
intensive vs. conventional insulin therapy on the development of long-term diabetesrelated complications.26 In the DDCT, the intensive insulin therapy group strived for strict
glycaemic control, with goal blood glucose levels as close to normal as possible, and a
target A1C in the normal range, i.e. <0.0605. However, despite not achieving as tight
control as targeted (mean A1C attained was 0.072), the intensive insulin therapy group
experienced a significant reduction in the onset and progression of microvascular and
neuropathic complications.26 Further epidemiologic analyses of the DCCT results
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demonstrated a continuous association between A1C and microvascular and
neuropathic complications, with no obvious threshold below which complications would
be completely prevented. For example, a 10% reduction in A1C was associated with a
43% lower risk of retinopathy progression.27 Taken together, these results highlight the
benefits of tight glycaemic control in patients with T1DM. Based on this evidence, the
CDA Clinical Practice Guidelines recommend tight glycaemic control, with a target A1C of
≤ 0.070, in most people with T1DM.2 However, it is also recommended that the target
A1C level be individualized for patients based on age, duration of T1DM, risk of severe
hypoglycaemia, and co-morbidities.2

2.5 Complications of Diabetes Mellitus and Its Management
Uncontrolled hyperglycaemia from suboptimally treated diabetes can result in acute and
chronic complications. However, over-aggressive treatment of hyperglycaemia can also
be detrimental as it may cause hypoglycaemia. Thus, the benefits of achieving tight
glycaemic control to prevent hyperglycaemic-related complications must always be
weighed against the risks of inducing hypoglycaemia.
2.5.1 Acute Complications of Uncontrolled Type 1 Diabetes
In those with T1DM, persistent untreated hyperglycaemia can lead to a hyperglycaemic
emergency termed diabetic ketoacidosis (DKA). DKA is characterized by hyperglycaemia,
anion gap metabolic acidosis, and ketone acid production due to insulin deficiency
(relative or absolute) and excess counter-regulatory hormones. It can be precipitated by
stressors including omission of insulin, infection, myocardial infarction, trauma, and
medications.
The incidence of DKA varies by age and sex but ranges between 4.6 – 8.0 per 1000
person-years among those with diabetes.28 In Ontario, the rate of hospitalization for
acute hyperglycaemia (including both DKA and hyperglycaemic hyperosmolar non-
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ketotic state, a related but distinct acute hyperglycaemic condition) in adults ≥ 20 years
old in 1999 was 458 per 100,000 people.29 There is a wide variation in the range of inhospital mortality for patients hospitalized for acute hyperglycaemia—reported
mortality in Ontario ranged from <1% in those age 20-34 up to ~16% in those age ≥ 75
years. 29
In the earlier days of IPT use, several studies observed that IPT was associated with
higher rates of DKA, most often related to pump infusion system malfunction,
interrupting the required basal delivery of insulin.30,31 In many cases, rising capillary
blood glucose values were noted by the patients, but the actual mechanical pump
problems (i.e. infusion set blockage, pump failure) were missed, leading to rapid loss of
glycaemic control and the development of DKA.30,31 With the advent of more
sophisticated technology, it was expected that mechanical pump failures would be less
frequent—though this has not been found to be the case.32,33 A recent study based on
patient responses to a standardized questionnaire showed that, even with current
modern insulin pump technology, problems with the infusion set, infusion site and pump
itself are still common, with most problems occurring within the first year of IPT.32 The
most common infusion set problems were kinking and blockage, the most common
infusion site problem was lipohypertrophy (occurring with long duration of IPT use), and
the most common pump problems were “no delivery”, keypad and battery problems.32
Guilhem et al.33 prospectively examined the occurrence of insulin pump failures over 6
years, and found that pump failure still occurs frequently, but with an important
difference as compared to the early days of IPT: despite the frequent occurrence of
pump failure, the major metabolic consequence of pump failure, DKA, was not seen in
the majority of patients.33 It was speculated that patient education and availability of 24hour on-call assistance were instrumental in helping to limit the development of DKA
after pump failure. These studies highlight the importance of appropriate education and
training for patients on IPT to help them recognize technical pump problems, and avoid
adverse consequences when they do develop.
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2.5.2 Chronic Complications of Uncontrolled Type 1 Diabetes
The chronic complications of T1DM can be classified as microvascular, macrovascular or
both. The major microvascular complications are retinopathy and nephropathy, while
the major macrovascular complications are coronary artery disease (CAD),
cerebrovascular disease (CVD), and peripheral vascular disease (PVD). Neuropathy can
be caused by both microvascular and macrovascular pathology.
Microvascular Complications
Strict glycaemic control can prevent the development of, or slow the progression of,
microvascular complications and neuropathy. In the DCCT,26 intensive therapy targeting
normoglycaemia both prevented the development and slowed the progression of
microvascular endpoints and neuropathy in people with T1DM.26 Intensive therapy
reduced the risks of the development of retinopathy by 76% and the progression of
retinopathy by 54%, and also reduced the occurrence of microalbuminuria, albuminuria,
and clinical neuropathy by 39%, 54% and 60%, respectively, in patients with T1DM.26
Retinopathy
Diabetic retinopathy is a broad term for damage to the retina caused by changes in the
retinal blood vessels in patients with diabetes, clinically characterized by the presence of
specific retinal lesions. In 2012, the estimated worldwide age-standardized prevalence of
any diabetic retinopathy was 77.3%, while that of vision-threatening retinopathy was
38.5%, in those with T1DM.34 In Canada, diabetic retinopathy is the main cause of
blindness in adults aged 30-69 years.35 However, detection and treatment of diabetic
retinopathy can decrease the risk of vision loss, and thus routine annual screening is
recommended for all people with T1DM starting 5 years after diagnosis.2 Treatment
options for retinopathy include laser therapy, vitrectomy, or intraocular pharmacological
therapy.
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Nephropathy
Diabetic nephropathy is defined as damage to the glomeruli of the kidney caused by
diabetes, resulting in increasing urinary protein excretion and subsequent impairment of
renal function. Diabetic nephropathy is the leading cause of end-stage renal disease
(ESRD) in Ontario and in Canada, with over 25% of the cases of ESRD attributed to
diabetes, both provincially and nationally.36 Annual screening for nephropathy is
recommended in T1DM starting 5 years after diagnosis.2 If nephropathy is present (or if
absent but the patient is hypertensive), medications to block the renin-angiotensinaldosterone system are of benefit. In normotensive patients with37-42 or without41
microalbuminuria, as well as in patients with overt nephropathy,43 treatment with
angiotensin-converting enzyme (ACE) inhibitors has been shown to slow the progression
of nephropathy. This benefit appears to occur independently from the effect of ACE
inhibitors in lowering blood pressure.44 Similarly, treatment with angiotensin II-receptor
blockers has been shown to slow nephropathy progression.45
Neuropathy
Diabetic neuropathy is comprised of a range of disorders involving nerve damage due to
diabetes. Population-based studies have shown that peripheral and autonomic
neuropathy in adults with T1DM is common with prevalences of 66% and 54%,
respectively.46,47 Similar to the recommendations for retinopathy and nephropathy
screening, peripheral neuropathy screening is recommended annually starting 5 years
after diagnosis of T1DM. As demonstrated in the DCCT,26 strict glycaemic control is key
in preventing and slowing progression of neuropathy, but if neuropathy is painful,
symptomatic relief may be attempted using anticonvulsants, antidepressants, opioids, or
topical nitrate spray.2
Macrovascular Complications
Strict glycaemic control has also been shown to be important in reducing the risk of
cardiovascular disease in T1DM. The DCCT demonstrated a non-significant trend toward
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decreased cardiovascular events with intensive therapy targeting normoglycaemia.48
The Epidemiology of Diabetes Interventions and Complications (EDIC) study49 is a longterm follow-up observational study to the DCCT, and it showed that intensive therapy
was associated with a 42% reduction in the risk for any cardiovascular disease event and
a 57% reduction in risk for the combined outcome of non-fatal myocardial infarction,
stroke, or death.
In addition to glycaemic control, other important measures to reduce cardiovascular risk
in T1DM are lifestyle and pharmacologic measures in the management of obesity,
hypertension and dyslipidemia, including physical activity and attention to diet, as well
as smoking cessation.2
2.5.3 Hypoglycaemia
Hypoglycaemia is a common consequence of insulin treatment. Clinically, it is
characterized by Whipple’s Triad: 1) the presence of autonomic or neuroglycopenic
symptoms, 2) a plasma glucose level <4.0 mmol/L, and 3) resolution of symptoms with
administration of carbohydrate. The severity of hypoglycaemia is classified as follows
according to the type of symptoms present and whether the patient is able to self-treat:
mild – autonomic symptoms and patient can self-treat, moderate – autonomic and
neuroglycopenic symptoms and patient can self-treat, severe – patient requires the
assistance of another person to treat.2 Risk factors for severe hypoglycaemia in patients
with T1DM include prior hypoglycaemia, especially tight glycaemic control as reflected
by a current A1C <6.0%, hypoglycaemic unawareness, long duration of T1DM, and
autonomic neuropathy.2 Severe hypoglycaemia in T1DM is common, with prior studies
reporting a prevalence between 30-40% per year,50-52 and an incidence between 1.153.20 events per person per year.53,54 Hypoglycaemia can have a profound negative
impact on quality of life, and can discourage patients from striving to achieve tight
glycaemic control.
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2.6 Insulin in Type 1 Diabetes Mellitus
Insulin is the mainstay of treatment in T1DM. There are a variety of insulin formulations
available in Canada with varying onset and peak duration of action (Table 1). The current
standard of care for intensive insulin therapy is use of either an MDI regimen or
continuous subcutaneous insulin infusion with an insulin pump.2
Insulin injections may be administered using syringes and needles or specially designed
insulin pens. In MDI regimens, a basal dose of insulin is given by injection with an
intermediate-acting insulin or a long-acting insulin analogue once or twice a day, while
bolus doses of insulin are given by injection with a short-acting insulin or a rapid-acting
insulin analogue at each meal.2 The goal of MDI regimens is to simulate normal
pancreatic secretion of insulin.

Table 1 – Insulin Formulations Available in Canada
Insulin Type

Generic and Brand Names

Basal or
Bolus
Basal

Long-acting basal
analogues

Glargine (Lantus)
Detemir (Levemir)

Intermediateacting

Humulin-N
Novolin ge NPH

Basal

Short-acting

Humulin-R
Novolin ge Toronto

Bolus

Rapid-acting
analogues

Aspart (NovoRapid)
Lispro (Humalog)
Glulisine (Apidra)
Humalog Mix 25
NovoMix 30
Humulin (30/70)
Novolin ge (30/70, 40/60, 50/50)

Bolus

Pre-mixed

Pharmacokinetics
Onset: 90 minutes
Peak: Not applicable
Duration: up to 24 hours
Onset: 1-3 hours
Peak: 5-8 hours
Duration: up to 18 hours
Onset: 30 minutes
Peak: 2-3 hours
Duration: 6.5 hours
Onset: 10-15 minutes
Peak: 1-2 hours
Duration: 3-5 hours

Adapted from the Canadian Diabetes Association 2009/10 Consumer’s guide to diabetes
products and medications12

13

Continuous subcutaneous insulin infusion with an insulin pump usually uses rapid-acting
analogues. Similar to MDI, IPT strives to mimic physiologic insulin secretion by the
pancreas by providing a continuous basal infusion of insulin throughout the day, with
boluses given as needed by the patient for meals.
The first subcutaneous insulin pump developed was the “Mill Hill infuser”, described in
1977 by Parsons et al.55 The first use of continuous subcutaneous insulin infusion in
patients with T1DM was in the United Kingdom56 and the United States.57
The current subcutaneous insulin pumps consist of a cartridge (reservoir) which may
hold up to 300 units of insulin, the pump mechanism (electronic computer components,
motor, piston), a battery, display screen and function buttons, and an infusion set
containing a small flexible cannula that is inserted under the skin (Figure 1). The original
insulin pumps were large, measuring 18.3 x 7.3 x 6.4 cm and weighing up to 400 grams.58
However, over the past 35 years the technology has greatly improved such that the
current pumps are much smaller and lighter (measuring approximately 8 x 5 x 2 cm and
88-110 grams).12 Current insulin pumps also have features for easier use, including the
ability to program multiple different basal rates of insulin delivery through the day,
bolus calculator functions to help calculate the appropriate bolus dose according to the
number of grams of carbohydrate consumed, and memory displays of insulin delivery.
As the technology develops further, more sophisticated pump features are being offered
including insulin pumps combined with continuous glucose monitoring systems (CGMS).
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Reproduced with permission from Didangelos T 2011 Diabetes Res Clin Pract 59

Figure 1 – Schematic of Insulin Pump and Related Supplies
Given the sophisticated features of modern insulin pumps, patients pursuing IPT must
undergo specialized training and education to learn not only the basics of using a pump
(i.e. infusion set insertion, basal rate programming and bolus dose delivery), but also
troubleshooting skills to manage technical pump problems. In addition, the usual
components of routine diabetes management are still required (i.e. frequent capillary
blood glucose monitoring, accurate carbohydrate counting at meals and snacks,
appropriate sick day management etc.).

2.7 Insulin Pump Therapy and Type 1 Diabetes Mellitus
2.7.1 Evidence for the Efficacy of Insulin Pump Therapy in Adults with Type 1 Diabetes
Mellitus
Many randomized controlled trials (RCTs) comparing the efficacy of IPT and MDI
programs in improving glycaemic control in T1DM have been performed, and several
meta-analyses have been done in recent years.3-11 All of the meta-analyses have shown a
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small but significant improvement in A1C levels with IPT as compared to MDI, though
the meta-analyses varied in the studies included, age of subjects (children and/or
adults), and types of insulin used in the MDI regimen (i.e. short and intermediate–acting
insulins vs. rapid and long-acting insulin analogues).3-11
Although it was not designed to compare the efficacy of IPT and MDI in achieving strict
glycaemic control, the DCCT provided observational evidence from the intensive therapy
group, who self-selected to either IPT or MDI.60 When data from participants with at
least 4.5 years of follow-up were analyzed according to mode of insulin delivery (IPT n =
124, MDI n=284), the IPT subgroup achieved A1C levels between 0.002-0.004 (i.e. 0.20.4%) lower compared to the MDI subgroup with both subgroups being similar in
important clinical and demographic characteristics (age, duration of T1DM, baseline
A1C).60
However, despite the RCT evidence supporting a beneficial effect of IPT use in improving
glycaemic control, there is limited observational evidence on the benefits of IPT in
routine clinical practice. It is not disputed that results from RCTs provide the strongest
level of evidence in answering a question about an intervention’s efficacy, but it is often
noted that RCT results may be less useful in answering the question of whether the
intervention works in routine clinical practice. The subjects of RCTs are usually a highly
selected and homogeneous population (as a result of strict inclusion and exclusion
criteria), and the intervention studied is given in a standardized manner under ideal
settings. These conditions are not the norm in the “real-world”. Outside of a RCT,
factors other than the intervention can influence the intervention’s effectiveness
including patient-specific and provider-specific factors.
Despite the meta-analyses of RCTs noted above that have shown a significant benefit of
IPT on glycaemic control, worldwide uptake of IPT use is variable. To our knowledge,
there have been 19 observational studies61-79 (17 prospective or retrospective cohort
studies, 2 cross-sectional studies) evaluating the association between IPT and glycaemic
control that, because they were observational, may provide a better indication of the
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effects of IPT in routine clinical practice (as compared to RCTs). However, even within
the observational studies there are differences in design that may not reflect routine
care ranging from algorithm-based protocol-driven cohort studies63 to studies of data
from regional71 or national73 IPT registries. Most of these studies have been performed
in Europe,62,65-68,70,71,73-77,79 with others in the United States,61,63,64 New Zealand,69
India,72 and Australia.78 No studies have been performed in Canada, and only 2
studies77,78 had a separate control comparison group of non-IPT users. A summary of
these observational studies is presented in Table 2.

Table 2 – Summary of Observational Studies of the Association Between Insulin Pump Therapy Use and Glycaemic Control
Author
(Year)

Type of Study

Separate
Control
Group?

Country
(Data Source)

# of subjects
with T1DM on
IPT

IPT Duration

Pre-IPT A1C
Mean ± SD

Mean A1C on IPT
(or change in A1C)

Mecklenburg61
(1985)

Prospective
cohort

N

United States
(3o care centre)

127

Mean 31.8 ± 8.37
mo

0.106 ± 0.002

0.089 ± 0.001 (at 1 yr)
0.089 ± 0.001 (at 2 yrs)
0.086 ± 0.002 (at 3 yrs)

Chanteleau62
(1989)

Prospective
cohort

N

Germany
(3o care centre)

116

Mean 4.5 yrs

0.077 ± 0.001

0.067 ± 0.001

Bode63
(1996)

Prospective
cohort

N

United States
(single centre)

55

Mean 3.1 yrs

0.077 ± 0.015

0.074 ± 0.012
(at 1 yr, n=55)
0.077 ± 0.017
(at 2 yrs, n=41)
0.074 ± 0.017
(at 3 yrs, n=26)
0.074 ± 0.012
(at 4 yrs, n=20)

Rudolph64
(2002)

Retrospective
cohort

N

United States
(3o care centre)

107

Mean 36.1 ± 25.5
mo

0.076

0.071

Mean 1.7 ± 1.5 yrs
(optimization grp)
Mean 1.9 ± 1.2 yrs
(severe hypo grp)

0.078 ± 0.012
(optimization grp)
0.076 ± 0.011
(severe hypo grp)

0.072 ± 0.008
(optimization grp)
0.072 ± 0.012
(severe hypo grp)

Mean 13.1 ± 6.3
yrs

0.085 ± 0.011
(n=87)

0.080 ± 0.012
(n=87)

0.094 ± 0.014

Mean change
-0.0115 ± 0.008

0.085 ± 0.014

0.073 ± 0.900

103
(60 for
optimization,
43 for severe
hypo)
117
(87 with preIPT data)

Linkeschova65
(2002)

Prospective
cohort

N

Germany
(3o care centre)

Nørgaard66
(2003)

Crosssectional

N

Denmark
(nationwide
audit)

Lepore67
(2005)

Retrospective
cohort

N

Italy
(3o care centre)

82

Pickup68
(2006)

Prospective
cohort

N

United Kingdom
(3o care centre)

30

Mean 31.9 ± 14.5
mo
(range 4-55 mo)
Median 5 mo
(IQR 3-9 mo)
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Reda 69
(2007)
Giménez70
(2007)

Retrospective
cohort
Prospective
cohort

Riveline71
(2008)

CrossSectional

N

Sudhakaran72
(2009)

Retrospective
cohort

N

Jankovec73
(2010)

Retrospective
cohort

N

Janez74
(2012)

Retrospective
cohort

N

N
N

New Zealand
(3o care centre)
Spain
(3o care centre)
France
(regional IPT
registry)
India
(3o care centre)
Czech
(national IPT
register)
Slovenia
(3o care centre
register)

78

Mean 3.0 ± 2.6 yrs

0.088 ± 0.014

0.079 ± 0.0100 (at 3 mo)
0.079 ± 0.0097 (at 6 mo)

153

Mean 2 yrs

0.079 ± 0.013

0.073 ± 0.011 (at 2 yrs)

0.091 ± 0.019
(n=339)

0.078 ± 0.014
(n=339)

0.106 ± 0.021

0.080 ± 0.016

285 T1DM
44 T2DM
17

Mean 3.5 ± 3.5 yrs
(total cohort
n=339)
Mean 2 yrs
(range 2-6 yrs)

730

Minimum 3 yrs

0.0965 ± 0.0007

184

Mean 3.8 ± 0.3 yrs

0.076 ± 0.009

68

2.2 yrs
(range 0-25 yrs)

0.080
(range
0.058-0.137)

0.076
(range 0.061-0.095)
(median follow-up 3 yrs)

50

6 mo

0.0804 ± 0.0116

0.0748 ± 0.009 (at 6 mo)

272

Minimum 5.5 yrs

0.0839 ± 0.0130

Crenier76
(2013)
Carlsson77
(2013)

Cohort
(retrospective
& prospective
data)
Retrospective
cohort
Retrospective
cohort

Cohen78
(2013)

Retrospective
cohort

Y

Australia
(3 care centre)

126

6 mo

0.080 ± 0.01

Grant79
(2013)

Cohort
(retrospective
& prospective
data)

N

United Kingdom
(3o care centre)

350

Range
6-12 mo

0.078
(total cohort
n=350)

Marmolin75
(2012)

N

N
Y

Denmark
(3 care centre
database)
o

Belgium
(3o care centre)
Sweden (EMR
from 10 clinics)
o

0.0824 ± 0.0007 (at 1 yr)
0.0834 ± 0.0007 (at 2 yrs)
0.0844 ± 0.0007 (at 3 yrs)
0.069 ± 0.009 (at 1 yr)
0.069 ± 0.006 (at 2 yrs)
0.070 ± 0.006 (at 3 yrs)

Mean change at 1 yr:
-0.0054
Mean change:
-0.0064 (at 6 mo, n=117)
-0.0060 (at 1 yr, n=102)
Mean change -0.010
(those without mental
health problems: n=171)

o

T1DM, type 1 diabetes mellitus; IPT, insulin pump therapy; A1C, glycated hemoglobin; SD, standard deviation; Y, yes; N, no; 3 ,tertiary; mo, months; yr, year;
grp, group, hypo, hypoglycaemia; EMR, electronic medical record
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2.7.2 “Real-World” Insulin Pump Therapy Use in Type 1 Diabetes Mellitus
The use of IPT in patients with T1DM varies worldwide but remains low in many
countries. Recent nationwide audits in the United Kingdom80,81 and Australia82 have
shown the prevalence of IPT use in T1DM to be 2-6% and 10%, respectively.
In Europe, reported IPT use rates in T1DM vary from <5% in Finland, Portugal, Spain, and
Russia,83,84 5-10% in Belgium, Czech Republic, Denmark, Greece, Hungary, Ireland, Italy,
Poland, and Slovakia,84 and >15% in Austria, France, Germany, the Netherlands, Norway,
Sweden and Switzerland.83-85
There are limited data on IPT use rates in T1DM in Asia, which may be related to the
small proportion of patients with T1DM in many Asian countries. In India, over 95% of
patients with diabetes have T2DM, and so IPT is used primarily in this population, with
only ~20% of IPT use in T1DM.86 Similarly, in China, only 30% of IPT use is in T1DM.87
The highest rate of IPT use in T1DM is in North America. In the United States, it is
estimated that ~40% of patients with T1DM use IPT.83 In Canada, the IPT use rate is
estimated to be between ~8-15% of eligible people (children and adults).88
The large variability in IPT use worldwide may be related to many factors, but
worldwide, a large barrier to IPT use remains the costs to patients and the health care
system. The major cost of IPT to the patient is the insulin pump and its associated
supplies, while the main costs to the health care system arise from delivery of IPTrelated services.80
2.7.3 Funding for Insulin Pump Therapy in Type 1 Diabetes Mellitus in Canada
In Canada, government funding to patients with T1DM for IPT and its associated supplies
is province-specific (Appendix A). Ontario was the first province to implement IPT
funding for children beginning January 2007 (retroactive to April 1, 2006). In September
2008, Ontario was also was the first province to initiate IPT funding for eligible adults
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through the MOHLTC ADP, with eligibility determined based on pre-specified clinical
criteria. The ADP collects demographic, glycaemic control and adverse event data (i.e.
hypoglycaemia) at program entry and on annual renewal.
Until very recently, Ontario was the only province to provide IPT funding to adults
(Alberta began IPT funding for residents of any age in June 2013). Prince Edward Island
remains the only province without funding for IPT (child or adult), while the other
provinces and territories only have coverage for children and young adults, with
differing age limits, eligibility criteria, coverage for pump supplies, and amount of
funding.
In Ontario, the ADP provides coverage for the full cost of the insulin pump on initial
application paid directly to the insulin pump supplier. The ADP also provides program
participants with a grant of $2,400.00 CAD per year (divided into quarterly payments) for
IPT-associated supplies.

2.8 Insulin Pump Therapy for Type 1 Diabetes Mellitus in London, Ontario
Care for adults with T1DM may be managed by Family Physicians, General Internists, or
Endocrinologists. As a tertiary care referral centre for Southwestern Ontario, SJHC
provides a regional resource for care of T1DM, and is the main IPT provider site for the
ADP within the South West Local Health Integration Network (Appendix B).
At SJHC, adults with T1DM who are interested in pursuing IPT through funding by the
ADP may be seen by 1 of 12 adult Endocrinologists in the Division of Endocrinology &
Metabolism at St. Joseph’s Hospital or by 1 of 2 Family Physicians with expertise in
diabetes at the PCDSP. To initiate the process, interested patients attend a “Pump
Information Class” held at the Diabetes Education Centre (DEC). They are then referred
by their physician for individual consultations with a registered IPT nurse (RN) and
dietitian (RD) at the DEC for a “Pre-ADP Assessment”. As part of this assessment,
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patients must demonstrate that they meet the ADP eligibility criteria (Appendix C). After
meeting the eligibility criteria, patients attend a “Pre-Pump Start Class” and
subsequently a “Pump Start Class” at the DEC, at which time they begin a 90 day trial
period of IPT. Once the trial has begun, their physician submits an application form on
their behalf to the ADP. On this form, clinical data on glycaemic control and adverse
events in the year prior are collected (2-3 most recent A1C values, number of episodes
of DKA and severe hypoglycaemia) (Appendix D). Other collected information includes
demographics, confirmation of eligibility, and the make and model of insulin pump
chosen by the patient. If the trial period is completed successfully, patients then
schedule follow-up education classes and individual RN and RD appointments as needed.
If a patient wishes to continue ADP-funded IPT past the first year, they must apply for a
renewal. To do so, they must continue to meet specific ongoing eligibility criteria
(Appendix C), and their physician is required to submit a renewal form to the ADP,
including their last 2 A1C values and number of hypoglycaemic episodes requiring thirdparty intervention (Appendix E). Application for repeated renewal of IPT funding is
required annually thereafter. Continued close contact with the patient’s diabetes
management team (physician, RN and RD) is required throughout the duration of their
participation in the program.

22

2.9 Summary
2.9.1 Research Question and Hypothesis
The main research question of this study was: does ADP-funded IPT improve glycaemic
control and adverse outcomes in adults with T1DM followed by the Diabetes Clinics at
SJHC?
It was hypothesized that ADP-funded IPT would improve glycaemic control and adverse
outcomes in adults with T1DM, as compared to adults with T1DM not on IPT, who are
followed by the Diabetes Clinics at SJHC.
2.9.2 Significance of the Research
Use of IPT for the management of T1DM is increasing. Clinical trials have shown that IPT
significantly improves glycaemic control in adults with T1DM as compared to insulin
treatment by MDI, though there is limited observational evidence on the benefits of IPT
in routine clinical practice in Canada, and any potential benefits may be highly
dependent on appropriate patient selection. Further, a major barrier that precludes
widespread use of IPT is the cost.
Ontario has been a leader in Canada in implementing funding for IPT—first for children,
and now adults. From the inception of the adult program in September 2008 until
December 31, 2012 the ADP has received 7,363 applications from adults in Ontario
seeking funding for IPT. However, to date, there has been no evaluation of the clinical
impact of ADP-funded IPT.
This study is the first to evaluate the effect of a provincially-funded program for insulin
pump therapy on glycaemic control and adverse outcomes in adults served by a tertiary
care diabetes referral centre in Canada.
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Chapter 3: Methods
3.1 Overview of Study Design
This study used a retrospective single-centre observational matched cohort design using
data from WebDR, the EMR system of the Diabetes Clinics at SJHC in London, Ontario,
and from physician paper charts. Patients with T1DM were identified, and from these
patients, a cohort of subjects on IPT was selected and individually matched to subjects
not on IPT, resulting in matched pairs of IPT subjects and control subjects (as described
below). Demographic and clinical characteristics were compared between the IPT and
control cohorts, while glycaemic control outcomes and adverse events were compared
for each pair before and after the IPT start date of each pair’s IPT subject.

3.2 Ethics Approval
This study was approved by the Western University Health Sciences Research Ethics
Board (Appendices F and G). No patient contact occurred and informed consent was not
required as the data used was secondary data collected as part of routine clinical care.

3.3 Data Sources
WebDR is a web-based EMR database system that was developed for clinical and
research use at SJHC (Appendix H). WebDR was populated from migration of data from
the DAD (a prior EMR used by select Diabetes Clinics in London over the past decade)
and by manual data entry from physician paper charts (performed in 2010-2011). Thus,
WebDR contains patient data from as early as 2000.
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Routine clinical use of WebDR began in September 2011 at the PCDSP and in October
2011 at St. Joseph’s Hospital. All patients seen at the Diabetes Clinics are assigned a
unique WebDR identification number and demographic, clinical, and laboratory data are
entered and/or updated at each visit by physicians, including residents, allied health
professionals (nurses and dietitians) or by a dedicated medical data entry clerk. As of
March 2013, WebDR contained clinical data from 15,478 patients with diabetes, of
whom 12,046 had information on type and duration of diabetes.
The researchable database of WebDR is a repository of de-identified data which is
stored on a separate server from the clinical application for security and confidentiality
purposes. However, the repository and clinical application are linked to allow for daily
data updates. There is one dedicated Database Manager with the unique ability to
perform queries of the researchable database.
For this study, data was extracted from WebDR. However, as this was the first use of
WebDR for research, for all data extraction the WebDR data was compared to the
physician paper chart to ensure accuracy and completeness of the study data. Where
WebDR data was missing or different compared to the physician paper chart, data from
the physician paper chart was extracted and used in the analyses.
Validation of WebDR data was performed (Appendix I). The gold standard for
comparison was the physician paper chart. A random sample of 10% of the study cohort
records was selected for validation, with 4 variables selected for validation (baseline A1C
value, baseline A1C date, follow-up A1C value, follow-up A1C date). Accuracy was
assessed according to 3 levels of agreement (match, no match, not recorded).
The overall level of agreement between WebDR and the reference standard was fair to
good, with a range of matches from 69.4% to 80.6%. There were no instances of “no
match”; however, the range of “not recorded” values was 19.4% to 30.6%.
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For all patient records, after completion of the validation, the data found to be missing
in WebDR were extracted from the physician paper chart and subsequently entered into
WebDR to improve its accuracy for future research use.

3.4 Study Population and Cohort Selection
The target population consisted of all adults age ≥ 19 years with T1DM followed by the
Diabetes Clinics at SJHC and who were entered into WebDR. Subjects on IPT (the insulin
pump therapy cohort) were entered into the study at their IPT start date (which could
be any time between September 1, 2008 and August 31, 2011) and data from 18 months
prior to their IPT start date until October 15, 2012 was collected. The time frame for IPT
start date was chosen to (a) coincide with the start of the Ontario MOHLTC ADP funding
of IPT for adults, and (b) to allow for data to be collected up until at least 13.5 months
after the latest possible IPT start date (i.e. August 2011). This minimum 13.5 month
follow-up period was chosen to allow for assessment of the primary outcome (glycated
hemoglobin, or A1C) at 1 year, and since A1C is an estimate of glycaemic control over ~
3 months, a window of 12 ± 1.5 months was selected. Subjects not on IPT (the matched
control cohort) were entered into the study according to the IPT start date of the pump
cohort subject to whom they were matched, and data from 18 months prior to study
entry until October 15, 2012 was collected. Subject follow-up length was variable
(Figure 2).
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IPT, Insulin Pump Therapy; ADP
ADP, Assistive Devices Program

tart and Data Collection
Figure 2 – Timeframes for IInsulin Pump Therapy Start
3.4.1 Definition of Type 1 Diabetes Mellitus
The diagnosis of T1DM was determined by an Endocrinologist at St. Joseph’s Hospital or
a Family Physician at the PCDSP
PCDSP, and either recorded in the physician’s
’s paper chart and
subsequently transferred to WebDR, or directly manually entered into WebDR at the
patient’s first visit to clinic. Subjects with T1DM were identified via a WebDR query of
diabetes type.
3.4.2 Assembly of the Insulin Pump Therapy Cohort
Subjects on IPT were identified via a WebDR query of me
medication
dication lists for insulin pumppump
compatible insulinss (i.e. rapid
rapid-acting analogues) and insulin doses (i.e. basal insulin rates
per hour and bolus insulin doses per gram of carbohydrate). Dates of IPT start (and IPT
stop, if applicable) were obtained from We
WebDR, or, if missing, from the physician’s
p
office
paper chart. However, the format of the documented IPT start date varied by subjects.
Some subjects had the full IPT start date
date—i.e. day, month, year—recorded,
recorded, while others
only had month and year. For all IPT subjects, month and year were extracted from
WebDR;; if this information was missing, it was obtained from the physician
hysician paper chart.
Within the paper chart, IPT start month and year were extracted from a copy of the
initial MOHLTC insulin
n pump ADP application form if available. However, if a copy of this
form was not in the paper chart, IPT start date was extracted from the SJHC DEC pump
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start class notification form (preferred) or a clinic progress note which documented the
IPT start month and year.
Only those patients who started IPT in September 2008 or later were considered for
inclusion, as this was the start month of the Ontario MOHLTC funding of IPT through the
ADP. Confirmation of IPT use was performed by cross-reference to the list of patients
who started on IPT maintained by the SJHC DEC. It was judged that this was an accurate
independent method of verification of IPT use during the time period of interest as it
was mandatory for all patients starting on ADP-funded IPT to be seen by an insulin pump
nurse and dietitian at the DEC prior to initiation of IPT.
3.4.3 Assembly of the Matched Control Cohort
Subjects not on IPT (and thus potential control subjects) were identified among
remaining patients with T1DM in WebDR who were not identified by the WebDR to be
using IPT. A WebDR query was performed to generate a list of these subjects, along with
their current age, and current duration of T1DM.
This study examined the relationship between IPT use and glycaemic control. As there
are many potential confounding factors for this relationship (i.e. factors associated with
both IPT use and with glycaemic control), matching was used to limit confounding bias.
The primary matching variable was duration of T1DM. The secondary matching variables
were current age and year of study entry. Matches were identified manually as
described below.
Control subjects were matched to IPT subjects starting with exact duration of T1DM in
years, and then matched as closely as possible for current age in years measured as the
absolute difference between the age of the IPT subject and the control subject. In
situations where there was more than 1 potential control subject with the same
absolute age difference compared to the IPT subject (e.g., if a potential control subject
was 2 years younger and another was 2 years older), the older subject was selected as
the matched control. If there was more than 1 potential control subject with the same
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age difference compared to the IPT subject (e.g. both were 2 years younger), the first
subject on the list was selected. The date of study entry of control subjects was the “t=0
date”, which was defined as the corresponding IPT start date of the IPT subject to whom
they were matched.
3.4.4 Inclusion Criteria
Patients were included if they were age ≥ 19 years of age at the time of study entry and
had a known diagnosis of T1DM for at least 1 year prior to study entry. The rationale for
only including those with T1DM for ≥ 1 year was that a) glycaemic control in the first
year after diagnosis may not necessarily be representative of long-term glycaemic
control, b) data from at least 1 year prior to study entry was required and c) to be
eligible to apply for ADP-funded IPT, patients had to demonstrate experience on an MDI
regimen for at least 1 year. It was also required that patients had a paper chart available
for review, and were actively followed by a SJHC physician during the time period of
interest.
Patients on IPT were included in the IPT cohort if they began IPT through the Diabetes
clinics at SJHC at age ≥ 19 years at some point between September 1, 2008 and August
31, 2011, and remained on IPT for at least 1 year. The rationale for these requirements
were that a) those who started IPT during this time were likely to have done so via ADP
funding, and b) data from 1 year after IPT start was required.
3.4.5 Exclusion Criteria
Patients were excluded if they a) were pregnant within 1 year prior to or within 1 year
after study entry, b) did not have a documented baseline A1C level within 18 months
before study entry or c) did not have any documented follow-up A1C measurements
after study entry. Pregnancy was a reason for exclusion as it is a time during which
stricter glycaemic targets are recommended.2
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3.5 Outcome Measures
The A1C level was used as the main measure of glycaemic control. The values and dates
of A1C measurements were extracted from WebDR (in which values were migrated from
the DAD and/or entered manually by trained individuals). If missing from the EMR,
values were obtained via review of physician paper charts.
The
he primary outcome measure was the pa
paired difference in the change in A1C from
baseline to follow-up
up between matched pairs of IPT and control subjects.
subjects This was
defined as: [(follow-up
up A1CIPT – baseline A1CIPT) – (follow-up A1Ccontrol – baseline
A1Ccontrol)]. The baseline A1C was defined as the most recent A1C value prior to the IPT
start or t=0 date, and was required to be within 18 months
nths prior to the IPT start or t=0
date. The follow-up A1C was defined as the A1C value closest to 12 months after the IPT
start or t=0 date; however, since A1C provides an estimate of glycaemia over ~3 months,
the window for the follow
follow-up A1C was 12 ± 1.5 months (10.5 - 13.5 months)
months (see Figure
3).

IPT, insulin pump therapy; A1C
A1C, glycated hemoglobin

Figure 3 – Definition of Primary Outcome

The secondary outcome measures were a) “the proportion of subjectss with optimal
glycaemic control at follow
follow-up” defined as the percentage of subjects with an
a A1C of ≤
0.070 at 12 ± 1.5 months post IPT start/t=0 date
date, and b) “the incidence of adverse events
at follow-up”” defined as the incidence of episodes of diabetic ketoacidosis (DKA)
(DKA and
severe hypoglycaemic events per 100 patient-years at each follow-up year (yearly
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follow-up for adverse events was based on the calendar year). Severe hypoglycaemia
was defined as hypoglycaemia requiring 3rd-party assistance.2 Adverse events were
continuous variables obtained via patient self-report, and were reported as incidence
rates separately for each type of event at baseline and at each follow-up year.

3.6 Cohort Characteristics – Insulin Pump Therapy and Control Cohorts
The following demographic and clinical characteristics were collected from WebDR
and/or physician paper charts at baseline, or at baseline and follow-up, for the IPT and
control cohorts: current age, gender, access to private drug plan, city of residence,
average yearly household income, physician of record, current duration of T1DM,
smoking status, complication status, body mass index (BMI), total daily insulin dose
(TDD), number of capillary blood glucose (CBG) monitoring checks per day, number of
insulin injections per day, CGMS use, and number of adverse events per year. Baseline
characteristics were those documented in the calendar year prior to the IPT start
year/t=0 year, while follow-up characteristics were those documented in the calendar
year after the IPT start year/t=0 year.
3.6.1 Demographic Characteristics
Current age
Current age was a continuous variable in years derived from the patient self-reported
year of birth. Current age was calculated as 2013 – (year of birth). The year 2013 was
chosen as the reference year for calculating the current age since data analysis was done
in the year 2013.
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Gender
Gender was coded as a dichotomous variable with 1 representing males and 0
representing females.
Access to Private Drug Plan
Access to a private drug plan at baseline was defined as access to any non-Ontario
Health Insurance Plan drug insurance coverage, and was obtained via patient self-report.
It was coded as a dichotomous variable, with 1 for “yes” and 0 for “no”.
City of Residence
City of residence at baseline was obtained via patient self-report. It was coded as a
dichotomous variable with 1 for London and 0 for any other city.
Average Yearly Household Income
Average yearly household income at baseline was a continuous variable in dollars
derived from linkage of patient self-reported postal code to data from the 2006 Census
of Canada. The Census of Canada obtains address information (including postal code)
and data on household income for each respondent allowing for calculation of average
yearly household income at the Forward Sortation Area (FSA) level, which is the first 3
characters of the postal code (as defined by Canada Post). Data from the 2006 Census of
Canada was obtained via Western University’s Equinox data delivery system.
Physician of Record
The physician of record was the physician responsible for the patient’s diabetes care.
The variable was categorized into a dichotomous variable as per the physician specialty,
with 1 for Endocrinologist and 0 for Family Physician.
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3.6.2 Clinical Characteristics
Current duration of T1DM
Current duration of T1DM was a continuous variable in years derived from either the
patient self-reported year of T1DM diagnosis or the patient self-reported age at T1DM
diagnosis. If the year of T1DM diagnosis was available, current duration of T1DM was
calculated as 2013 – (year of T1DM diagnosis). As above, 2013 was used as the reference
year since data analysis was done in 2013. If the age at T1DM diagnosis was available,
the year of T1DM diagnosis was calculated as (year of birth) + (age at T1DM diagnosis),
and then duration of T1DM subsequently calculated.
Smoking status
Smoking status at baseline was obtained via patient self-report, and coded as a
dichotomous variable with 1 for “current smoking” and 0 for “no current smoking”.
Complication Status
The complication status at baseline was obtained via patient self-report. The specific
complications were cerebrovascular disease, coronary artery disease, peripheral
vascular disease, retinopathy, nephropathy and neuropathy, and were each coded as a
dichotomous variable with 1 for “presence of complication” and 0 for “absence of
complication”. The frequency of each complication was reported separately, and also
reported grouped into the dichotomous variables “at least 1 complication” (defined as
the presence of any 1 or more complication) and “at least 1 glycaemic-responsive
complication” (defined as the presence of at least 1 of retinopathy, nephropathy or
neuropathy), with 1 for “presence” and 0 for “absence”.
Body Mass Index
Body Mass Index (BMI) was a continuous variable in kg/m2 derived from the height and
weight of each patient (calculated as weight/height2). Data on BMI was collected at
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baseline and at yearly follow-up. Height was either patient self-reported or measured at
the initial clinic visit, and weight was measured by clinic staff at each clinic visit.
Total Daily Insulin Dose
The total daily insulin dose (TDD) at baseline was a continuous variable in units derived
from the patient self-reported basal and bolus insulin doses. It was calculated as (total
basal insulin doses per day) + (total bolus insulin doses per day).
Capillary Blood Glucose Monitoring Checks
The number of capillary blood glucose monitoring checks (CBG) per day, at baseline and
at yearly follow-up, was a continuous variable obtained via patient self-report.
Insulin Injections
The number of insulin injections per day, at baseline (IPT cohort) or at baseline and
yearly follow-up (control cohort), was a continuous variable obtained via patient selfreport.
CGMS Use
Use of a CGMS was a dichotomous variable, obtained via patient self-report. It was
defined as “ever CGMS use”, with 1 for “yes” and 0 for “no”.

3.7 Insulin Pump Therapy-Related Characteristics
For the IPT cohort, the following IPT-related characteristics were collected: age at IPT
start, brand of insulin pump, year of ADP application, year of insulin pump trial start and
wait time from DEC referral to DEC appointment for the ADP process.
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3.7.1 Age at Insulin Pump Therapy Start
Age at insulin pump therapy start, in years, was a continuous variable derived from the
documented year of insulin pump therapy start (from WebDR or physician paper chart)
and patient self-reported year of birth, calculated as (year of pump start) – (year of
birth).
3.7.2 Brand of Insulin Pump
The brand of insulin pump was a categorical variable obtained from a copy of the initial
MOHLTC ADP insulin pump application form in the physician paper chart. If this was not
available, data on brand of insulin pump was extracted from clinic progress notes. The
variable was coded as 1 for Medtronic, 2 for Animas or 0 for other.
3.7.3 Year of ADP Application and Year of Insulin Pump Trial Start
Year of ADP application and year of insulin pump trial start were coded as categorical
variables based on the calendar year of the dates of ADP application and insulin pump
trial start documented on a copy of the initial MOHLTC insulin pump ADP application
form in the physician paper chart. Years were coded as follows: 0 for 2008, 1 for 2009, 2
for 2010, 3 for 2011 and 4 for missing. Of note, the variables 2008 and 2011 were not
full 12 month years, given that window for IPT start date was from September 2008 until
August 2011, so the variable 2008 represents data from 4 months (SeptemberDecember 2008) and 2011 represents data from 8 months (January-August 2011), while
the variables 2009 and 2010 represent data from the full 12 month calendar years.
Further, whether a copy of the initial MOHLTC insulin pump ADP application form was
kept in the paper chart varied by physician, and therefore some data on year of ADP
application and year of insulin pump trial start was missing.
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3.7.4 Wait time from DEC Referral to Appointment
Wait time from DEC referral to appointment in months was a continuous variable based
derived from the dates of DEC referral and DEC appointment documented in a copy of
the initial MOHLTC insulin pump ADP application form in the physician paper chart.
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3.8 Power Calculation
An a priori power calculation was performed prior to the start of the study. It was
estimated that between 100-250 adults with T1DM from the Diabetes Clinics at SJHC
were on ADP-funded IPT. Given this range in sample size, assuming α=0.05 and β=0.20,
and estimating the standard deviation of the mean change in A1C over 1 year to be
0.00048, or 0.048% (as per WebDR data from all adult patients with T1DM in 2010), the
smallest detectable difference in the mean change in A1C over 1 year between the IPT
and control cohorts was between 0.00019, or 0.019% (for n=100 per group) and
0.00012, or 0.012% (for n=250 per group) (Table 3).

Table 3 – Power Calculation and Smallest Detectable Difference in Change in A1C
Sample Size Per Group

SD of change
in A1C (σ∆)
0.048%
2

2

50

100

150

200

250

300

0.027%

0.019%

0.016%

0.013%

0.012%

0.011%

2

δ = [(Z +Z ) * 2σ ]/n
α

β

Δ

where:
Δ = mean change in A1C in control cohort over 1 year
c

Δ = mean change in A1C in IPT cohort over 1 year
p

σ = SD of change in A1C over 1 year = 0.048%
Δ

δ = smallest detectable difference between Δ and Δ
c

p

n = sample size per group
and assuming α = 0.05, β = 0.20
SD, standard deviation; A1C, glycated hemoglobin; IPT, insulin pump therapy
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3.9 Statistical Analysis
Statistical analysis was performed using SAS for Windows (version 9.3). Demographic
and clinical characteristics were summarized using means and standard deviations or
proportions where applicable. The level of significance for all statistical tests was 0.05,
unless otherwise stated.
3.9.1 Comparison of Included and Excluded IPT Subjects
The age, duration of T1DM and gender of the included and excluded IPT subjects were
compared using independent samples t-tests (means) or Chi-square test (proportions),
as appropriate.
3.9.2 Paired Comparisons
Paired comparisons were performed to compare the current demographic
characteristics and baseline clinical characteristics of the IPT and control cohorts, using
paired t-tests (means) or McNemar’s test (proportions) as appropriate. Paired t-tests
were also performed to compare the mean A1C at baseline and follow-up and the mean
difference in A1C change scores between the IPT and control cohorts. McNemar’s test
was used to compare the proportions of subjects with an optimal A1C at baseline and
follow-up within each cohort, and to compare the proportions of subjects with an
optimal A1C between the IPT and control cohorts. Negative binomial regression was
used to compare the incidence of adverse events between cohorts at baseline (i.e. 1
year pre-IPT start/t=0) and at each follow-up year.
3.9.3 Missing Data and Imputation
Two pre-specified analyses were performed. The analyses differed depending on the
definition of the timing of the follow-up A1C, and whether imputation for missing data
was performed, as follows:
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Analysis 1: The follow-up A1C was defined as the A1C value closest to 12 months postIPT start/post-t=0 within a window of ± 1.5 months (i.e. 10.5-13.5 months) post-IPT
start/post-t=0. For subjects without a follow-up A1C between 10.5-13.5 months post-IPT
start/post-t=0, the missing data were not imputed and they were excluded from the
analysis.
Analysis 2: The follow-up A1C was defined as the A1C value closest to 12 months postIPT start/post-t=0 within a window of ± 1.5 months (i.e. 10.5-13.5 months) post-IPT
start/post-t=0. For subjects without a follow-up A1C in this window but who had an A1C
value between 0 -10.5 months post-IPT start/post-t=0, their follow-up A1C level in the
analysis was imputed by the “last observation carried forward” (LOCF) method, which
effectively widened the window for follow-up A1C in this analysis to 0-13.5 months postIPT start/post t=0. Those subjects who only had follow-up A1C values >13.5 months
post-IPT start/post t=0 were excluded from the analysis.
The proportion of subjects who were missing follow-up A1C values in the IPT vs. control
cohorts were compared using McNemar’s test. In addition, the baseline characteristics
of the subjects with missing follow-up A1C data were compared to those subjects with
non-missing follow-up A1C data within each cohort using two-sample t-tests, Chi-square
tests, or Fisher’s Exact test, where appropriate.
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3.9.4 Sensitivity Analyses
Effect of Wider Age Differences in Age-Matched Pairs
Since some of the matched IPT-control pairs were not matched within a ± 5 year age
difference, a sensitivity analysis was done excluding these pairs to determine if a wider
age difference between IPT-control pairs had an effect on the glycaemic outcomes.
Effect of Imputing Follow-Up A1C values from <6 Months Post-IPT Start/t=0
The use of LOCF to impute missing follow-up A1C values assumed that the follow-up, but
missing, A1C value did not significantly change from when it was measured to when it
was carried forward. However, since A1C is a measure of glycaemia over ~3 months, the
further from the defined 10.5-13.5 month follow-up window that it was measured (i.e.
the closer to IPT start/t=0), the less likely this assumption was to hold true. Therefore, a
sensitivity analysis was done using LOCF of only A1C values measured between 6-10
months post-IPT start/t=0 to determine if carrying forward values from earlier than 6
months post-IPT start/t=0 had an effect on the glycaemic outcomes.
3.9.5 Subgroup Analyses
Exploratory analyses were done to examine whether the baseline A1C influenced the
change in A1C from baseline to follow-up in each cohort. The analysis was performed
separately within each cohort stratified according to baseline A1C into 3 subgroups: ≤
0.070, 0.071 to 0.080, and ≥ 0.081. For both the IPT and control cohorts, paired t-tests
were done to compare the baseline and follow-up A1C in each subgroup. Baseline TDD
was also calculated for each subgroup and compared by one-way analysis of variance
(ANOVA) to assess for differences in baseline insulin dose that could contribute to
differences seen in the change in A1C. If the subgroups were significantly different by
ANOVA, post-hoc analysis with the Tukey-Kramer test was performed to determine
which groups differed.
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Chapter 4: Results
4.1 Study Cohorts
4.1.1 Insulin Pump Therapy Cohort
There were 229 patient records identified by WebDR and 224 patient records identified
by the DEC list of adults with T1DM who started IPT between September 1, 2008 and
August 31, 2011. Of these, 105 were common to both sources, resulting in 348 unique
patient records. Both the WebDR record and physician paper chart record were
reviewed for 347 of the patients (1 paper chart was not available for review), and 180
patients were found to meet the inclusion criteria. However, a further 6 patients were
excluded, resulting in a final IPT cohort of 174 patients (Figure 4).
Therefore, there were 174 patients on IPT who were not included in the analysis.
Comparing the final IPT cohort to those IPT patients who were not included in the study
showed that the patients on IPT who were not included were significantly younger
(p<0.001), and more likely to be female (p=0.038), but had a similar duration of T1DM
(Table 4).
4.1.2 Matched Control Cohort
Control subjects were first matched to IPT subjects by exact duration of T1DM in years,
and then by closest age in years. The age differences of the pairs were normally
distributed, and 84.5% (n=147) of the 174 IPT-control pairs were matched within ± 5
years (Figure 5).
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Adult patients with T1DM started on insulin pump therapy at SJHC
between September 2008 and August 2011 identified via WebDR
and DEC list of pump starts
WebDR (229)

DEC (224)
N = 105

N = 124

N = 119

348 unique patient records

NOT INCLUDED (N=168)
Pump start prior to Sept 2008
N=129
Pump start prior to being seen at SJHC N=10
Pump start prior to age 19
N=8
No longer followed/inactive record
N=8
Pump start after August 2011
N=3
Pump start during pregnancy
N=3
Pregnancy within 1 year of pump start
N=2
Never started on pump
N=2
Pump start prior to 2009 (date unknown) N=1
Pump therapy duration <1 year
N=1
Paper chart not available for review
N=1

180 patients who met inclusion criteria
EXCLUDED (N=6)
No pre-pump A1C value available
No post-pump A1C value available
Not able to be matched
(no T1DM diagnosis date)
FINAL INSULIN PUMP THERAPY PATIENT SAMPLE
N = 174
T1DM, type 1 diabetes mellitus; SJHC, St. Joseph’s Health Care; DEC, Diabetes Education
Centre; A1C, glycated hemoglobin

Figure 4 – Insulin Pump Therapy Cohort Selection

N=4
N=1
N=1
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Table 4 – Comparison of Final Insulin Pump Therapy Cohort vs. Insulin Pump Therapy
Patients Not Included/Excluded

Variables

Age (years)
Duration of T1DM (years)
Sex (Male) – n (% )

Final IPT
Cohort
n=174
45.0 ± 12.8
25.2 ± 13.1
80 (46.0)

IPT Patients not
included/excluded
n=174
39.8 ± 13.2
23.5 ± 11.8*
61 (35.1)

p-value
<0.001†
0.205†
0.038‡

IPT, insulin pump therapy; T1DM, type 1 diabetes mellitus
Data are mean values ± SD or number and frequency
*
9 patients of those not included/excluded were missing data on duration of T1DM
Comparison between groups using †two sample t-test or ‡Chi-square test

(%)
84.5%

Figure 5 – Distribution of Age Differences Between Matched Pairs of Insulin Pump Therapy and Control Subjects
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4.2 Baseline Cohort Characteristics
The baseline demographic characteristics are shown in Table 5. Given that the duration
of T1DM and current age were the matching variables, as expected these did not differ
significantly between the IPT and control cohorts. The mean duration of T1DM of both
cohorts was 25.2 ± 13.1 years. The mean current age was 45.0 ± 12.8 years for the IPT
cohort and 45.3 ± 13.2 years for the control cohort (p=0.350). There was no significant
difference in gender, city of residence, or average yearly household income between the
cohorts (all p>0.05). However, a significantly higher proportion of control subjects
(17.2%, n=30) than IPT subjects (6.9%, n=12) had a private drug plan (p=0.006), and a
significantly lower proportion of control subjects (91.4%, n=159) than IPT subjects
(97.1%, n=169) were followed by an Endocrinologist for their T1DM (p=0.031).

Table 5 – Baseline Demographic Characteristics of the Insulin Pump Therapy and
Control Cohorts

Age (years)
Duration of T1DM (years)
Gender (Male) – n (%)
Private Drug Plan - n (%)
City (London) - n (%)
Physician (Endocrinologist) – n (%)
Average Yearly Household Income
(CAD)

IPT Cohort
n=174
45.0 ± 12.8
25.2 ± 13.1
80 (46.0)
12 (6.9)
80 (46.0)
169 (97.1)

Control Cohort
n=174
45.3 ± 13.2
25.2 ± 13.1
97 (55.8)
30 (17.2)
90 (51.7)
159 (91.4)

$70,922 ± $12,850

$70,528 ± $13,942

IPT, insulin pump therapy; T1DM, type 1 diabetes mellitus; N/A, not applicable
Data are mean values ± SD or number and frequency
Comparison between cohorts using †paired t-test or ‡McNemar’s test

p-value
0.350†
N/A
0.100‡
0.006‡
0.358‡
0.031‡
0.799†
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The baseline clinical characteristics of each cohort are shown in Table 6. There was no
significant difference in baseline A1C between the IPT and control cohorts (IPT: 0.078 ±
0.011 vs. control: 0.078 ± 0.013, p=0.586), nor any significant difference between the
proportions of IPT and control subjects with an optimal (i.e. ≤ 0.070) baseline A1C (IPT:
25.3%, n=44 vs. control: 24.7%, n=43, p=1.000). Similarly, there was no significant
differences between the proportions of IPT and control subjects with a baseline A1C ≤
0.073 (IPT: 35.1%, n=61 vs. control: 34.5%, n=60) or ≤ 0.075 (IPT: 43.7%, n=76 vs.
control: 43.7%, n=76) (both p=1.000). The cohorts also did not differ significantly in their
baseline BMI, total daily insulin dose, or number of insulin injections per day.
However, there was a significantly lower proportion of current smokers in the IPT cohort
(4.0%, n=7) than the control cohort (19.0%, n=33) (p<0.001). Further, the proportion of
subjects with at least one diabetes-related complication was significantly lower in the
IPT cohort (34.5%, n=60) than the control cohort (44.8%, n=78) (p=0.044). Similarly, the
proportion of subjects with at least one glycaemic-responsive complication was
significantly lower in the IPT cohort (33.3%, n=58) than the control cohort (43.7%, n=76)
(p=0.047). These differences in diabetes-related complications appeared to be mediated
by a difference in the prevalence of neuropathy between the cohorts (IPT: 10.9%, n=19
vs. control: 19.0%, n=33, p=0.034). The IPT cohort also had a significantly higher mean
baseline number of CBG checks per day compared to the control cohort (IPT: 4.0 ± 0.8
vs. control: 3.7 ± 0.9, p=0.003).
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Table 6 – Baseline Clinical Characteristics of the Insulin Pump Therapy and Control
Cohorts
IPT Cohort
n
Baseline A1C
% with optimal* baseline A1C – n (%)
Current smoking – n (%)
At least 1 complication – n (%)
At least 1 glycaemic-responsive§
complication – n (%)
Complications – n (%)

CVD
CAD
PVD
Retinopathy
Nephropathy
Neuropathy

Baseline BMI (kg/m2)
Baseline TDD (units)
Baseline # CBG/day
Baseline # insulin injections/day

0.078 ± 0.011
44 (25.3)
7 (4.0)
60 (34.5)
58 (33.3)
0 (0)
6 (3.5)
1 (0.6)
39 (22.4)
25 (14.4)
19 (10.9)
26.4 ± 4.7
52.2 ± 25.6
4.0 ± 0.8
4.2 ± 0.5

Control Cohort
n

156
161
163
168

76 (43.7)
2 (1.2)
6 (3.5)
0 (0)
51 (29.3)
37 (21.3)
33 (19.0)
27.3 ± 5.5
58.1 ± 33.7
3.7 ± 0.9
4.2 ± 0.7

Pairs
included in
analysis, n

0.586†
1.000‡
<0.001‡
0.044‡

0.078 ± 0.013
43 (24.7)
33 (19.0)
78 (44.8)
174

p-value

174

149
170
158
168

0.047‡
N/A
1.000‡
N/A
0.162‡
0.111‡
0.034‡
0.281†
0.101†
0.003†
0.794†

IPT, insulin pump therapy; A1C; glycated hemoglobin; CVD, cerebrovascular disease; CAD,
coronary artery disease; PVD, peripheral vascular disease; BMI, body mass index; kg, kilogram;
m, meter; TDD, total daily insulin dose; CBG, capillary blood glucose
Data are mean values ± SD or number and frequency
Due to missing data, not all 174 pairs were compared for all variables
*

Optimal A1C defined as ≤ 0.070
Glycaemic-responsive complications include retinopathy, nephropathy and neuropathy
Comparison between cohorts using †paired t-test or ‡McNemar’s test

§

174

135
157
148
162
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A large number of subjects in both cohorts were missing data on the use of CGMS and
the number of adverse events at baseline. Only 2 IPT subjects documented use of CGMS,
while data on CGMS use was missing for the other 172 IPT subjects and all 174 control
subjects. For adverse events at baseline, in those with available data, there were no
documented episodes of DKA at baseline in either cohort (number of subjects with data
for DKA: n=36 IPT cohort, n=48 control cohort) but there were 17 episodes of severe
hypoglycaemia in 125 IPT cohort subjects at baseline and 15 episodes of severe
hypoglycaemia in 115 control cohort subjects at baseline. The corresponding baseline
incidences for severe hypoglycaemia were not significantly different between cohorts:
13.6 events per 100 patient-years in the IPT cohort and 13.0 events per 100 patientyears in the control cohort (p=0.946 negative binomial regression).
The pump therapy-related characteristics of the IPT cohort are shown in Table 7. The
mean age at the start of IPT was 41.8 ± 12.7 years, and the mean duration of T1DM at
the start of IPT was 22.0 ± 13.0 years. The majority (88.5%, n=154) of the IPT cohort used
a Medtronic pump. The distribution of the timing of both ADP applications and ADP
pump trial starts varied from 2008-2011 (though 2008 and 2011 were incomplete years).
The mean wait time from referral to the SJHC DEC until the DEC appointment for the
ADP process was 2.3 ± 2.4 months (wait time data available for only 69 subjects).
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Table 7 – Pump Therapy-Related Characteristics of the Insulin Pump Therapy Cohort

Age at Pump Start (years)
Duration of T1DM at Pump Start (years)
Brand of Pump – n (%)
Medtronic
Animas
Year of ADP application – n (%)
2008*
2009
2010
2011*
Missing
Year of ADP Pump trial start – n (%)
2008*
2009
2010
2011*
Missing

IPT Cohort
n=174
41.8 ± 12.7
22.0 ± 13.0
154 (88.5)
20 (11.5)
14 (8.1)
83 (47.7)
38 (21.8)
21 (12.1)
18 (10.3)
4 (2.3)
54 (31.0)
51 (29.3)
36 (20.7)
29 (16.7)

IPT, insulin pump therapy; T1DM, type 1 diabetes mellitus; ADP, Assistive Devices Program
Data are mean values ± standard deviation or number and frequency
*
partial years – 2008 includes 4 months (September-December) and 2011 includes 8 months
(January-August)

49

4.3 Cohort Characteristics at Follow-Up
The mean BMI and mean number of CBG per day in each year following IPT start (IPT
cohort) or t=0 (control cohort) are shown in Figure 6A and B. The mean number of
insulin injections per day in each year following t=0 for the control cohort is shown in
Figure 7.
The mean BMI of the IPT cohort in the IPT start year was 26.5 ± 4.7 kg/m2 (n=154), and
at t=0 year in the control cohort was 27.5 ± 6.3 kg/m2 (n=142). The mean BMI of the IPT
cohort at year 4 post-IPT start was 27.0 ± 4.4 kg/m2 (n=5), while the mean BMI of the
control cohort at year 4 post-t=0 was 25.9 ± 4.2 kg/m2 (n=5) (Figure 6A).
The mean number of CBG per day in the IPT cohort at IPT start year was 3.9 ± 0.5
(n=157), and at t=0 year in the control cohort was 3.7 ± 1.0 (n=152). At year 4 post-IPT
start/t=0, the mean number of CBG per day was 4.0 ± 0.0 in the IPT cohort (n=4) and 3.5
± 1.0 in the control cohort (n=4) (Figure 6B).
The mean number of insulin injections per day in the control cohort at t=0 year was 4.2 ±
0.6 (n=167), while the mean number of insulin injections per day at year 4 post-t=0 was
4.3 ± 0.5 (n=4) (Figure 7).
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A)
Mean Body Mass Index (kg/m2)

34.0
32.0
30.0
28.0
IPT

26.0

Control
24.0
22.0
20.0
0

1

2

3

4

Year Post-IPT Start/t=0

B)

5

Mean Number of Capillary Blood
Glucose Checks per Day

Number of Subjects
IPT
Control

4

154
142

158
148

119
102

54
52

5
5

IPT

3

Control
2
1
0
0

1

2

3

4

Year Post-IPT Start/t=0
Number of Subjects
IPT
Control

157
152

161
152

115
100

48
47

4
4

IPT, insulin pump therapy
Error bars represent standard deviation
Year 0 is the IPT start year (IPT cohort) or t=0 year (control cohort)
Data were classified as per calendar year, and length of follow-up was variable, thus not all
subjects had data for each year (sample size at each year provided)

Figure 6 – Mean Body Mass Index and Mean Number of Capillary Blood Glucose
Checks Per Day at Yearly Follow-Up for Insulin Pump Therapy and Control Cohorts
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Mean Number of Insulin Injections
per Day

6.0
5.0
4.0
Control
3.0
2.0
1.0
0.0
0

1

2

3

4
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4

Year after t=0
Number of Subjects
Control

167

167

105

Error bars represent standard deviation
Year 0 is the t=0 year
Data were classified as per calendar year, and length of follow-up was variable, thus not all
subjects had data for each year (sample size at each year provided)

Figure 7 – Mean Number of Insulin Injections Per Day at Yearly Follow-Up for Control
Cohort

4.4 Glycaemic Control Outcomes
The timing of the follow-up A1C measurement varied by subject. The distribution of the
timing of the follow-up A1C measurement for each cohort is shown in Figure 8. For both
cohorts, the timing of the follow-up A1C measurements was normally distributed. The
mean time for the follow-up A1C measurement was 11.7 ± 2.0 months post-IPT start
(IPT cohort) and 11.4 ± 4.4 months post-t=0 date (control cohort); these were not
significantly different (p=0.369 paired t-test).

91.4%
85.1%

81.0%
52.9%

30.0%

25.0%

Frequency (%)

20.0%

15.0%

IPT
Control

10.0%

5.0%

0.0%
1

3

5

7

9

10.5

12

13.5

15

17

19

21

23

25

27

Months Post
Post-IPT Start or t=0 Date

A1C,, glycated hemoglobin; IPT, insulin pump therapy

Figure 8 – Distribution of Timing of Follow-Up
Up A1C Measurements for Insulin Pump Therapy and Control Cohorts
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Analysis 1 required that the follow-up A1C be between 10.5 – 13.5 months post-IPT
start/post-t=0 date—if no A1C was measured in this window, the subject was excluded
from the analysis. As seen in Figure 8, 81.0% (n=141) of IPT subjects and 52.9% (n=92) of
control subjects had follow-up A1C measurements between 10.5 – 13.5 months.
Analysis 2 required that the follow-up A1C be between 10.5 – 13.5 months post-IPT
start/post-t=0 date. However, if no A1C was measured in this window, but an A1C
measurement between 0 – 10.5 months post-IPT start/post-t=0 date was available, the
subject was included and the follow-up A1C was imputed using LOCF. If no A1C
measurement between 0 – 13.5 months post-IPT start/t=0 date was available for a
subject, they were excluded from the analysis. As seen in Figure 8, 91.4% (n=159) of IPT
subjects and 85.1% (n=148) of control subjects had follow-up A1C measurements
between 0 – 13.5 months.
4.4.1 Change in A1C
The mean baseline A1C, mean follow-up A1C, and mean change in A1C from baseline to
follow-up for each cohort are shown in Table 8.
Insulin Pump Therapy Cohort
The mean baseline A1C in the IPT cohort was 0.078 ± 0.011. In Analysis 1, the mean
follow-up A1C was 0.075 ± 0.009, for a mean change in A1C of -0.002 ± 0.009. In Analysis
2, the mean follow-up A1C was 0.075 ± 0.010, for a mean change in A1C of -0.002 ±
0.009. In both analyses, the change in A1C from baseline to follow-up was statistically
significant (Analysis 1, p=0.009; Analysis 2, p=0.002).
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Table 8 – Mean A1C at Baseline and Follow-Up, and Mean Change in A1C for Insulin
Pump Therapy and Control Cohorts

Cohort

Analysis

Baseline A1C
n=174

Follow-Up A1C
n

IPT

(1)
(2)

0.078 ± 0.011

0.075 ± 0.009
0.075 ± 0.010

Control

(1)
(2)

0.078 ± 0.013

0.078 ± 0.014
0.080 ± 0.013

Change in A1C
(Follow-Up – Baseline)

p-value*

141
159

-0.002 ± 0.009
-0.002 ± 0.009

0.009
0.002

92
148

0.000 ± 0.010
0.001 ± 0.010

0.952
0.487

A1C, glycated hemoglobin; IPT, insulin pump therapy
Data are presented as mean values ± standard deviation
*
Comparison of baseline vs. follow-up A1C using paired t-test

Control Cohort
The mean baseline A1C in the control cohort was 0.078 ± 0.013. In Analysis 1, the mean
follow-up A1C was 0.078 ± 0.014, for a mean change in A1C of 0.000 ± 0.010. In Analysis
2, the mean follow-up A1C was 0.080 ± 0.013, for a mean change in A1C of 0.001 ±
0.010. In both analyses, the change in A1C from baseline to follow-up was not
statistically significant (Analysis 1, p=0.952; Analysis 2, p=0.487).
4.4.2 Paired Difference in A1C Change Score
The mean paired difference in A1C change scores between matched pairs of IPT and
control subjects is shown in Table 9. In Analysis 1, the mean paired difference in the A1C
change score was -0.003 ± 0.015, which was not statistically significant (p=0.126).
However, in Analysis 2, the mean paired difference in the A1C change score was -0.003 ±
0.015, which was statistically significant (p=0.041).
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Table 9 – Mean Paired Difference in A1C Change Score for Matched Pairs of Insulin
Pump Therapy and Control Subjects

Analysis
(1)
(2)

Paired Difference in A1C Change Scores
(IPT Change in A1C – Control Change in A1C)
-0.003 ± 0.015
-0.003 ± 0.015

p-value*
0.126
0.041

Pairs included in
analysis, n
74
133

A1C, glycated hemoglobin; IPT, insulin pump therapy
Data are presented as mean values ± standard deviation
*
Comparison of A1C change score for each matched IPT-control pair using paired t-test

4.4.3 Optimal A1C at Baseline and at Follow-Up
The proportions of subjects with an optimal A1C at baseline compared to follow-up in
each cohort are shown in Table 10. “Optimal” A1C was defined as an A1C ≤ 0.070.
Insulin Pump Therapy Cohort
In Analysis 1, the proportion of IPT subjects with an optimal A1C at baseline was 27.0%
(n=38), and at follow-up was 33.3% (n=47). These were not significantly different
(p=0.163). In Analysis 2, the proportion of IPT subjects with an optimal A1C at baseline
was 25.8% (n=41) and at follow-up was 32.1% (n=51), and these were also not
significantly different (p=0.143).
Control Cohort
In Analysis 1, the proportion of control subjects with an optimal A1C at baseline and at
follow-up were 22.8% (n=21) and 26.1% (n=24), respectively. These were not
significantly different (p=0.607). In Analysis 2, the proportions of control subjects with
an optimal A1C at baseline and follow-up were the same—both were 23.0% (n=34).

56

Table 10 – Difference in Proportion of Subjects with an Optimal A1C at Baseline vs. at
Follow-Up in Insulin Pump Therapy and Control Cohorts
Cohort

Analysis

Optimal A1C at
Baseline

Optimal A1C at
Follow-Up

p-value*

Pairs included
in analysis, n

IPT

(1)
(2)

38 (27.0)
41 (25.8)

47 (33.3)
51 (32.1)

0.163
0.143

141
159

Control

(1)
(2)

21 (22.8)
34 (23.0)

24 (26.1)
34 (23.0)

0.607
1.000

92
148

A1C, glycated hemoglobin; IPT, insulin pump therapy
Data are presented as number (percentage)
*
Comparison of proportion at baseline vs. at follow-up using McNemar’s test

However, given that the target “optimal” level of A1C should be individualized according
to patient-specific factors, we repeated the analyses using pre-specified higher, but still
clinically relevant, threshold levels (A1C ≤ 0.073 and ≤ 0.075), and these results are
shown in Tables 11A and 11B. In the IPT cohort in both Analysis 1 and 2, there was a
significantly higher proportion of subjects with an A1C ≤ 0.073 at follow-up (Analysis 1:
46.1%, n=65; Analysis 2: 45.3%, n=72) than at baseline (Analysis 1: 36.2%, n=51; Analysis
2: 35.2%, n=56) (Analysis 1: p=0.034, Analysis 2: p=0.023). Similarly, in both Analysis 1
and 2, there was a significantly higher proportion of subjects with an A1C ≤ 0.075 at
follow-up (Analysis 1: 55.3%, n=78; Analysis 2: 55.4%, n=88) than at baseline (Analysis 1:
44.0%, n=62; Analysis 2: 43.4%, n=69) (Analysis 1: p=0.014, Analysis 2, p=0.005).
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Table 11 – Difference in the Proportion of Subjects with an A1C ≤ 0.073 and ≤ 0.075 at
Baseline vs. at Follow-Up in Insulin Pump Therapy and Control Cohorts
A)
Cohort

Analysis

A1C ≤ 0.073 at
Baseline

A1C ≤ 0.073 at
Follow-Up

p-value

IPT

(1)
(2)

51 (36.2)
56 (35.2)

65 (46.1)
72 (45.3)

0.034
0.023

141
159

Control

(1)
(2)

33 (35.9)
50 (33.8)

36 (39.1)
48 (32.4)

0.581
0.839

92
148

Cohort

Analysis

A1C ≤ 0.075
at Baseline

A1C ≤ 0.075
At Follow-Up

p-value

IPT

(1)
(2)

62 (44.0)
69 (43.4)

78 (55.3)
88 (55.4)

0.014
0.005

141
159

Control

(1)
(2)

44 (47.8)
63 (42.3)

46 (50.0)
66 (44.6)

0.815
0.701

92
148

*

Pairs included in
analysis, n

B)
*

Pairs included in
analysis, n

A1C, glycated hemoglobin; IPT, insulin pump therapy
Data are presented as number (percentages)
*
Comparison of proportion of subjects at baseline vs. at follow-up using McNemar’s test

However, this pattern was not seen within the control cohort—there was no significant
difference in the proportions of control subjects with an A1C ≤ 0.073 or an A1C ≤ 0.075
at follow-up compared to at baseline in either Analysis 1 or 2.
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The proportions of subjects with an optimal A1C at follow-up (i.e. ≤ 0.070) were
compared between the IPT and control cohorts, and the results are shown in Table 12.
In Analysis 1, there were no significant differences between cohorts in the proportions
of subjects with an optimal follow-up A1C. However, in Analysis 2, the IPT cohort had a
significantly higher proportion of subjects with a follow-up A1C ≤ 0.070 (33.8%, n=45)
compared to the control cohort (21.8%, n=29) (p=0.044).

Table 12 – Difference in the Proportion of Subjects with Follow-Up A1C ≤ 0.070 in
Matched Pairs of Insulin Pump Therapy and Control Subjects

Analysis

IPT

Control

p-value*

(1)
(2)

23 (31.1)
45 (33.8)

18 (24.3)
29 (21.8)

0.487
0.044

Pairs included in
analysis, n
74
133

A1C, glycated hemoglobin; IPT, insulin pump therapy
Data are presented as number (percentage)
*
Comparison of proportion of subjects in IPT vs. control cohorts using McNemar’s test
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4.5 Adverse Events
The number of episodes of DKA and severe hypoglycaemia per calendar year were
collected for each subject in the 1 year prior to IPT start/t=0 year (baseline), the year of
IPT start/t=0, and yearly thereafter. Due to varying length of follow-up and missing data,
not all subjects had adverse event data for each follow-up year. There were no DKA
episodes reported for either cohort at any follow-up year (number of subjects with data
on DKA: IPT start/t=0 year n=23 (IPT), n=49 (control); year 1 n=30 (IPT), n=46 (control);
year 2 n=18 (IPT), n=37 (control); year 3 n=10 (IPT), n=23 (control), year 4 n=3 (IPT), n=2
(control)). The incidence of severe hypoglycaemic events at baseline and after 1 year
post-IPT start/t=0 is shown in Figure 9. As shown previously, there was no significant
difference in the incidence of severe hypoglycaemia between cohorts in the 1 year prior
to IPT start/t=0 (baseline). However, after 1 year post-IPT start/t=0, the IPT cohort had a
significantly lower incidence of severe hypoglycaemia (2 events in 149 patients, for an
incidence of 1.3 events per 100 patient-years) compared to the control cohort (14
events in 124 patients, for an incidence of 11.3 events per 100 patient years) (p=0.016).
There was no significant difference in the incidence of severe hypoglycaemia between
cohorts in year 2 (IPT: 2.9 per 100 patient-years vs. control: 3.8 per 100 patient-years,
p=0.743) or year 3 (IPT: 2.6 per 100 patient-years vs. control: 7.3 per 100 patient years,
p=0.376) post-IPT start/t=0. No episodes of severe hypoglycaemia were reported in
either cohort in year 4 post-IPT start/t=0.

Incidence of Severe Hypoglycaemic Events
per 100 Patient-Years
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13.6

13.0

IPT

14
11.3

Control

12
10
8
6
4

*
1.3

2
0
1 year pre
pre-IPT
start/t=0

Number of Subjects
IPT
Control

125
115

1 year post-IPT
start/t=0

149
124

IPT, insulin pump therapy
Data were classified as per calendar ye
year, and length of follow-up was variable, thus not all
subjects had data for each year (sample size at each year provided)
*p=0.016 IPT vs. control, negative binomial regression

Figure 9 – Incidence of Severe Hypoglycaemic Events in the 1 Year Pre-IPT
Pre
Start/t=0
(baseline) and After 1 Year Post-IPT Start/t=0 for Insulin Pump Therapy and Control
Cohorts
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4.6 Missing Data – Follow-Up A1C Values
The proportion of subjects with missing follow-up A1C values in each analysis for each
cohort was compared. In Analysis 1, 82 control subjects (47.1%) and 33 IPT subjects
(19.0%) were missing follow-up A1C values in the pre-specified time window, and the
proportion in the control cohort was significantly higher than the IPT cohort (p<0.001).
However, in Analysis 2, after using LOCF to impute missing values in 56 (32.2%) control
and 18 (10.3%) IPT subjects, there was no significant difference between cohorts in the
proportion of subjects missing follow-up A1C values (control: n=26, 14.9% vs. IPT: n=15,
8.6%, p=0.117).
The baseline characteristics between those with missing vs. non-missing follow-up A1C
values were compared for each cohort (Appendices J and K).
Insulin Pump Therapy Cohort
In Analysis 1, there were 33 IPT subjects with missing follow-up A1C data. Compared to
IPT subjects without missing A1C data, those with missing A1C data had a significantly
lower mean baseline BMI (25.2 ± 3.6 kg/m2, n = 30 vs. 26.8 ± 4.9 kg/m2, n=126, p=0.049)
and lower mean baseline TDD (43.8 ± 18.4 units, n=30 vs. 54.1 ± 26.6 units, n=131,
p=0.014). There were no differences in any other baseline characteristics between these
two groups (Appendix J).
In Analysis 2, there were 15 IPT subjects with missing follow-up A1C data. There were no
significant differences in baseline characteristics between these subjects and the 159 IPT
subjects who were not missing A1C data (Appendix J).
Control Cohort
In Analysis 1, there were 82 control subjects with missing follow-up A1C data. Compared
to control subjects without missing A1C data, those with missing A1C data had a
significantly lower mean baseline TDD (52.8 ± 25.4 units, n=81 vs. 62.9 ± 39.4 units,
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n=89; p=0.048) and were less likely to have a private drug plan (11.0%, n=9 vs. 22.8%,
n=21; p=0.039). There were no differences in any other baseline characteristic between
these two groups (Appendix K).
In Analysis 2, there were 26 control subjects with missing follow-up A1C data. There
were no significant differences in baseline characteristics between these subjects and
the 148 control subjects who were no missing A1C data (Appendix K).

4.7 Sensitivity Analyses
Effect of Wider Age Differences in Age-Matched Pairs
Of the 174 IPT-control pairs, 27 (15.5%) were not matched within a ± 5 year age
difference. A sensitivity analysis including only the 147 pairs that were matched within
this window of age differences showed similar results as presented above—a significant
change in A1C was seen from baseline to follow-up in the IPT cohort but not in the
control cohort (IPT: -0.002 ± 0.010, p=0.006 (Analysis 1); -0.003 ± 0.010, p=0.001
(Analysis 2); Control: 0.000 ± 0.011, p=0.967 (Analysis 1); 0.001 ± 0.011, p=0.369
(Analysis 2)) and a significant paired difference in change in A1C for matched IPT-control
pairs was seen in Analysis 2 only (Analysis 1: -0.003 ± 0.016, p=0.119; Analysis 2: -0.004 ±
0.016, p=0.013).
Effect of Imputing Follow-Up A1C values from <6 Months Post-IPT Start/t=0
In Analysis 2, 18 (10.3%) IPT subjects and 56 (32.2%) control subjects had follow-up A1C
values imputed using LOCF of values measured between 0-10 months post-IPT start/t=0.
A sensitivity analysis imputing the follow-up values of only the 16 (9.2%) IPT subjects and
40 (26.4%) control subjects whose follow-up A1C were measured between 6-10 months
post-IPT start/t=0 showed similar results as presented above—a significant change in
A1C from baseline to follow-up was seen in the IPT cohort but not the control cohort
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(IPT: -0.002 ± 0.010, p=0.002; Control: 0.000 ± 0.011, p=0.616) and a significant paired
difference in change in A1C for matched IPT-control pairs was seen (-0.003 ± 0.015,
p=0.049).

4.8 Subgroup Analysis
The mean baseline and follow-up A1C, and the mean change in A1C from baseline to
follow-up for both cohorts stratified by baseline A1C are shown in Tables 13 and 14.
Three subgroups were defined according to the following A1C levels: ≤ 0.070, 0.071 to
0.080, and ≥ 0.081. The baseline TDD was also compared between subgroups.
Insulin Pump Therapy Cohort
Analysis 1:
In the subgroup with baseline A1C ≤ 0.070, the A1C significantly increased from baseline
to follow-up (mean baseline A1C 0.065 ± 0.004 and mean follow-up A1C 0.069 ± 0.007)
for a mean A1C change of 0.004 ± 0.008 (p<0.01). In the subgroup with baseline A1C ≥
0.081, the A1C significantly decreased from baseline to follow-up (mean baseline A1C
0.088 ± 0.009 and mean follow-up A1C 0.081 ± 0.009) for a mean A1C change of -0.007 ±
0.009 (p<0.0001). However, for the subgroup with baseline A1C 0.071 to 0.080, there
was no significant change in A1C from baseline to follow-up (Table 13A).
Analysis 2:
A similar pattern was seen for Analysis 2. In the subgroup with baseline A1C ≤ 0.070, the
A1C significantly increased from a mean baseline A1C of 0.065 ± 0.004 to a mean followup A1C of 0.069 ± 0.007, for a mean A1C change of 0.004 ± 0.008 (p=0.004). In the
subgroup with baseline A1C ≥ 0.081, the A1C significantly decreased from a mean
baseline A1C of 0.088 ± 0.009 to a mean follow-up A1C of 0.081 ± 0.010, for a mean A1C
change of -0.007 ± 0.009 (p<0.0001).

Table 13 – Subgroup Analysis: Mean A1C at Baseline and Follow-Up, Mean Change in A1C and Mean Baseline Total Daily Insulin
Dose for Insulin Pump Therapy Cohort - Stratified by Baseline A1C
A)
Baseline A1C

Analysis

Subgroup

(1)

≤ 0.070
0.071 – 0.080
≥ 0.081

0.065 ± 0.004
0.076 ± 0.003
0.088 ± 0.009

n
44
66
64

(2)

≤ 0.070
0.071 – 0.080
≥ 0.081

0.065 ± 0.004
0.076 ± 0.003
0.088 ± 0.009

44
66
64

Insulin Pump Therapy Cohort
Follow-Up A1C
Change in A1C
n
(Follow-Up – Baseline)
0.069 ± 0.007
38
0.004 ± 0.008
0.074 ± 0.008
49
-0.001 ± 0.008
0.081 ± 0.009
54
-0.007 ± 0.009
0.069 ± 0.007
0.074 ± 0.008
0.081 ± 0.010

41
58
60

0.004 ± 0.008
-0.002 ± 0.008
-0.007 ± 0.009

<0.01
0.249
<0.0001

Pairs included
in analysis, n
38
49
54

0.004
0.148
<0.0001

41
58
60

p-value*

B)
Subgroup
≤ 0.070
0.071 – 0.080
≥ 0.081

Baseline Total Daily Dose (units)
n
46.7 ± 24.1
42
52.8 ± 25.5
60
55.5 ± 26.5
59

p-value†
0.229

A1C, glycated hemoglobin
Data are presented as mean ± standard deviation
*
Comparison of baseline and follow-up A1C values within each subgroup by paired t-test
†
Comparison of baseline total daily dose between subgroups by one-way ANOVA
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Table 14 - Subgroup Analysis: Mean A1C at Baseline and Follow-Up, Mean Change in A1C and Mean Baseline Total Daily Insulin
Dose for Control Cohort - Stratified by Baseline A1C
A)

Analysis

Subgroup

(1)

≤ 0.070
0.071 – 0.080
≥ 0.081

(2)

≤ 0.070
0.071 – 0.080
≥ 0.081

0.064 ± 0.004
0.076 ± 0.003
0.091 ± 0.011

n
43
68
63

Control Cohort
Follow-Up A1C
n
0.067 ± 0.007
21
0.076 ± 0.007
40
0.089 ± 0.017
31

0.064 ± 0.004
0.076 ± 0.003
0.091 ± 0.011

43
68
63

0.068 ± 0.008
0.077 ± 0.007
0.090 ± 0.014

Baseline A1C

34
58
56

Change in A1C
(Follow-Up – Baseline)
0.003 ± 0.006
0.001 ± 0.006
-0.003 ± 0.016

p-value*
0.034
0.301
0.310

Pairs included
in analysis, n
21
40
31

0.004 ± 0.006
0.001 ± 0.005
-0.002 ± 0.015

0.001
0.094
0.346

34
58
56

B)
Subgroup
≤ 0.070
0.071 – 0.080
≥ 0.081

Baseline Total Daily Dose (units)
n
44.3 ± 28.2
43
47.8 ± 24.4
66
59.2 ± 33.4
62

p-value†
0.019‡

A1C, glycated hemoglobin
Data are presented as mean ± standard deviation
*
Comparison of baseline and follow-up A1C values within each subgroup by paired t-test
†
Comparison of baseline total daily dose between subgroups by one-way ANOVA
‡
As per the Tukey-Kramer test, the mean baseline total daily dose was significantly different between the subgroups with baseline A1C ≤0.070
and ≥0.081 (p<0.05)
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However, in the subgroup with baseline A1C 0.071 to 0.080, there was again no
significant change in A1C from baseline to follow-up (Table 13A). There was no
significant difference in baseline TDD between subgroups (Table 13B).
Control Cohort
Analysis 1:
In the subgroup with baseline A1C ≤ 0.070, the A1C significantly increased from baseline
to follow-up (mean baseline A1C 0.064 ± 0.004 and mean follow-up A1C 0.067 ± 0.007)
for a mean A1C change of 0.003 ± 0.006 (p=0.034). However, there was no significant
change in A1C from baseline to follow-up in either the subgroup with baseline A1C 0.071
to 0.080 or the subgroup with baseline A1C ≥ 0.081 (Table 14A).
Analysis 2:
Similarly, in Analysis 2, only the subgroup with baseline A1C ≤ 0.070 showed a significant
change in A1C from baseline to follow-up (mean baseline A1C 0.064 ± 0.004 and mean
follow-up A1C 0.068 ± 0.008), for a mean A1C change of 0.004 ± 0.006 (p=0.001). The
subgroups with baseline A1C 0.071 to 0.080 and baseline A1C ≥ 0.081 did not show any
significant change in A1C from baseline to follow-up (Table 14A).
However, there was a significant difference in the baseline TDD among the 3 subgroups
in the control cohort (p=0.019) (Table 14B). The subgroup with a baseline A1C ≤ 0.070
had a significantly lower baseline TDD than the subgroup with a baseline A1C ≥ 0.081
(p<0.05).
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4.9 Summary of Results
This retrospective cohort study ascertained a group of adult IPT users funded by the
MOHLTC ADP, and compared their glycaemic control at approximately 1 year after IPT
start to a cohort of control subjects matched by T1DM duration and age. Data on
adverse outcomes at baseline and follow-up (yearly up to 4 years post-IPT start/t=0)
were also collected.
Subjects in the IPT cohort had a significant decrease in A1C from baseline to 1 year
follow-up of 0.002 (or 0.2%), while the A1C level in the control cohort did not change. In
the matched analysis, the mean paired difference in A1C change score between the IPT
and control cohort subjects was -0.003, i.e. the mean improvement (decrease) in A1C
was 0.003 (or 0.3%) more in the IPT cohort than in the control cohort. Subjects in the
IPT cohort were more likely to have an optimal A1C at follow-up compared to those in
the control cohort.
No subjects in either cohort had any episodes of DKA at baseline or at yearly follow-up.
The baseline incidence of severe hypoglycaemic events was similar in both cohorts, but
after 1 year post-IPT start/t=0, the IPT cohort had a significantly lower incidence of
severe hypoglycaemia compared to the control cohort.
Exploratory subgroup analyses suggested that the effect of IPT use on the change in A1C
differed according to baseline A1C where an improvement in A1C was seen in IPT
subjects with baseline A1C levels ≥ 0.081, but a worsening in A1C was seen in IPT
subjects with baseline A1C levels ≤ 0.070. No change was seen in those with baseline
A1C levels 0.071 to 0.080.
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Chapter 5: Discussion
5.1 Introduction
Insulin pump therapy is becoming an increasingly utilized method of insulin
administration in T1DM, and as of September 2013, the provincial government funding
program subsidizing its use in adults in Ontario has been in place for 5 years. In mid2013, Alberta implemented an IPT funding program for residents of all ages, but
otherwise, no other province in Canada provides financial support for IPT in adults with
T1DM.
There are no Canadian studies that have examined the impact of a provincial funding
program for IPT in adults. Despite RCT evidence3-11 showing that IPT causes a small but
significant improvement in glycaemic control, there is limited “real-world” evidence for
the benefits of IPT on glycaemic control and adverse outcomes. Prior observational
studies,61-79 primarily in Europe, have been performed in small cohorts of adults with
T1DM, but the majority of the studies did not have a control group, and most were in
subjects with poor glycaemic control at baseline (i.e. baseline A1C values ≥ 0.080).
Duration of IPT also varied widely between studies.61-79
The objective of our study was to compare glycaemic control and adverse outcomes at 1
year between a cohort of adult IPT users funded by the ADP and a control cohort,
matched by age and T1DM duration in order to determine the impact of ADP-funded IPT
in adults with T1DM in Ontario under “real-world” conditions.
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5.2 Summary of Key Findings & Comparison with Previous Research
5.2.1 Characterization of Insulin Pump Therapy Cohort
The IPT cohort included 174 adults with a mean current age of 45.0 years (mean age at
IPT start 41.8 years), mean current duration of T1DM of 25.2 years (mean duration at IPT
start 22.0 years), and approximately equal numbers of males and females (80/94). They
were overweight, with a mean BMI of 26.4 kg/m2, and very few (4%) were current
smokers. Almost all (97.1%) were followed by an Endocrinologist, and slightly less than
half (46%) lived in London. Their average yearly household income was $70,922, and
very few (6.9%) had access to private drug plan coverage. The subjects had fairly good
glycaemic control prior to initiating IPT with a mean baseline A1C of 0.078, and with
25.3% of the cohort having a baseline A1C ≤ 0.070. Approximately one third had at least
1 glycaemic-responsive complication (i.e. retinopathy, nephropathy or neuropathy) at
baseline.
The age and duration of T1DM of published observational cohorts of IPT users have
varied. In general, the mean age and duration of T1DM at the time of IPT start in our IPT
cohort (mean age 41.8 years, mean duration 22 years) was similar to that of IPT users in
previous studies (mean age range 29 to 50.5 years, mean duration range 9.3-29 years).6179

Of note, the duration of IPT use in previous observational studies was markedly different
compared to our cohort. We characterized our IPT cohort from 1 year pre-IPT start until
up to 4 years post-IPT start, though length of follow-up varied by subject based on year
of IPT start (the mean available follow-up was 2.2 ± 0.8 years post-IPT start). To assess
the change in glycaemic control while on IPT, we specifically examined the time period
between 1 year pre- and 1 year post-IPT start. In previous studies61-79, the mean
duration of IPT use ranged from 6 months to 13.1 years.
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Furthermore, the cohorts of IPT users in previous observational studies61-79 had poorer
glycaemic control at baseline compared to our IPT cohort—the mean baseline A1C of
the IPT cohorts in the previous 19 studies was 0.085 (range 0.077-0.106), whereas our
IPT cohort had fairly good glycaemic control at baseline (mean baseline A1C 0.078).
5.2.2 Comparison of Insulin Pump Therapy and Control Cohorts
The matched control cohort in our study included 174 adults who had similar baseline
characteristics to the IPT subjects with some exceptions: fewer control subjects were
followed by an Endocrinologist, more control subjects had private drug plan coverage,
more control subjects were current smokers, and more control subjects had at least 1
glycaemic-responsive complication (specifically neuropathy). The control cohort also
performed a lower mean number of CBG checks per day at baseline.
Taken together, except for the difference in private drug plan coverage, these baseline
clinical differences between the control and IPT cohorts suggest that our control cohort
was less invested in their health and T1DM self-care relative to our IPT cohort. It is
interesting to note that, despite these differences, there was no difference in baseline
glycaemic control between the IPT and control cohorts, with the same mean baseline
A1C of 0.078 and a similar proportion (24.7%) with a baseline A1C ≤ 0.070.
5.2.3 Glycaemic Control Outcomes
Change in A1C from Baseline to Follow-Up
At approximately 1 year post-IPT start, our IPT subjects had a significant decrease in A1C
compared to baseline. The mean follow-up A1C in the IPT cohort was 0.075, which,
while still suboptimal, represented a mean change in A1C of -0.002 from baseline in the
IPT users (Analysis 1 and 2). At the same time, a similar decrease in A1C from baseline
was not seen in our control subjects—their mean follow-up A1C ranged from 0.078
(Analysis 1) to 0.080 (Analysis 2) which yielded a statistically and clinically non-significant
mean change in A1C over 1 year of 0 to +0.001 from baseline.
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Of the prior 19 observational studies evaluating the association between IPT and
glycaemic control, 18 also showed a significant decrease in A1C with IPT use.61,62,64-79
Four studies67,77-79 also reported a mean change in A1C from baseline to follow-up in IPT
users, and showed slightly greater changes in A1C (range -0.0054 to -0.0115) as
compared to our study. However, these studies defined their follow-up A1C differently
than our study. Two of these studies77,78 also examined the change in A1C in a control
group of non-IPT users. A summary comparing our results with the results of those
studies reporting changes in A1C in the IPT group from baseline to follow-up and the
difference in change in A1C between the IPT and control groups is shown in Table 15.
Table 15 – Comparison of Results: Current Study and Prior Studies Reporting Change in
A1C from Baseline to Follow-Up in Patients on Insulin Pump Therapy and Difference in
Change in A1C Between Insulin Pump Therapy and Control Group

Change in A1C from
Baseline to Follow-up
(mean ± SD)

Difference between
groups for change in
A1C at Follow-up
(mean ± SD)
-0.003 ± 0.015

Author
(Year)

Country
(Data
Source)

Liu
(current
study)

Canada
(3o care
centre)

IPT:
Control:

159
148

1 year

Carlsson77
(2013)

Sweden
(EMR
from 10
clinics)

IPT: -0.0054 ± 0.0111
260
Control: -0.0003 ± 0.0086 2,213

1 year

Cohen78
(2013)

Australia
(3o care
centre)

IPT:
Control:

1 year

not reported

Grant79
(2013)

N/A

Lepore67
(2005)

-0.002 ± 0.009
0.001 ± 0.010

n

Timing of
Follow-Up

-0.006
-0.001

102
105

United
Kingdom
(3o care
centre)

IPT: -0.010
(no control group)

171

6-12
months

Italy
(3o care
centre)

IPT: -0.0115 ± 0.0084
(no control group)

82

3 months

(unadjusted
paired difference,
n=133 pairs)

-0.0051 (unadjusted)
-0.0042 (adjusted)

N/A

A1C, glycated hemoglobin; SD, standard deviation; IPT, insulin pump therapy; 3o, tertiary; EMR,
electronic medical record; N/A, not applicable
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Carlsson et al.77 performed a retrospective cohort study in 272 subjects on IPT,
measuring A1C at 1, 2 and 5 years of IPT use (the primary outcome was at 5 years). The
mean change in A1C at 1 year in the IPT subjects was -0.0054, which was statistically
significant. For their primary outcome determination at 5 years, they used a large time
window (5 years ± 6 months) for A1C measurement. As well, they defined A1C at 1 year
as the first A1C value after 1 year, but did not specify the time window for
measurement, making it unclear whether the 1 year value also was subject to the same
large time window. In our study, our pre-specified window for follow-up A1C was
relatively narrow (12 ± 1.5 months); this difference may partly explain why we observed
a smaller mean change in A1C in our IPT cohort. Carlsson et al.77 also studied a matched
control group of non-IPT users (matched by the IPT start date ± 182 days), with an
average of 9 matched controls per IPT user and a total control group of 2437 subjects.
Similar to what we observed in our control cohort, their control group did not have a
significant change in A1C from baseline to 1 year (mean change -0.00033).
Grant et al.79 retrospectively examined the impact of mental health problems on
glycaemic control in 350 patients with T1DM on IPT. In the subgroup of IPT users
without a history of mental health problems (n=171), the mean change in A1C from
baseline to follow-up was -0.010, which was statistically significant. However, in this
study, the time window for the follow-up A1C used for analysis was again relatively large
being between 6-12 months post-IPT start. This difference may explain why we observed
a smaller mean change in A1C.
Cohen et al.78 performed a retrospective cohort study of 126 subjects newly started on
IPT, and examined the change in A1C from baseline at 6 and 12 months, and then yearly
from 2 until 5 years. The peak A1C reduction in the IPT group was -0.0064 at 6 months,
with a statistically significant reduction of -0.0060 persisting at 1 year. However, the A1C
values used in their analyses were the means of all A1C measurements in that time
period (i.e. in the first 6 months, 12 months, and the mean for each subsequent year),
which may contribute to the greater change in A1C as compared to what we saw in our
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study. In addition, unlike our study, the control cohort in Cohen et al. had a significant
reduction in A1C of -0.0015 (at 6 months), but their control subjects participated in a
structured 5 week education program (including 2.5 hour group meetings per week),
similar to the DAFNE (Dose Adjustment For Normal Eating) program.89 This education
program may explain why the control subjects in their study experienced a small but
significant change in A1C at 6 months. However, at 1 year, the change in A1C in their
control group was not significant.
Lepore et al.67 conducted a retrospective cohort study in 82 subjects on IPT in which
they examined A1C values which were measured every 3 months while subjects were on
IPT (with mean IPT duration 31.9 ± 14.5 months). They showed a significant mean
change in A1C of -0.0115 over this time, but, as in Cohen et al.,,78 the follow-up A1C
value used in the analysis was the mean of all follow-up A1C measurements. Thus, their
longer duration of follow-up with multiple A1C determinations may have allowed for
detection of a greater change in A1C.
In the current study, it was felt that the use of a single A1C value measured within the
defined follow-up period was a more clinically relevant outcome measure, as opposed to
the mean of all A1C values measured within that time. Using a mean of all measured
A1C values may provide a broad reflection of the overall glycemic control in a time
period, but it may not clearly illustrate the magnitude of change in A1C. For example, in
2 subjects both with baseline A1C values of 0.080 and each with 2 subsequent follow-up
A1C values—subject one with follow-up values of 0.090 then 0.070, and subject two
with follow-up values of 0.100 then 0.060 —their mean follow-up A1C would be the
same (0.080), giving a 0% change compared to baseline for both subjects, when in
actuality both had a significant improvement in A1C compared to baseline, as per their
second follow-up A1C values of 0.070 and 0.060, respectively.
One study63 did not demonstrate a significant decrease in A1C from baseline to followup in IPT users. Bode et al. performed a prospective cohort study in which 55 patients
with T1DM with severe recurrent hypoglycaemia and/or suboptimal glycaemic control
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(A1C ≥ 0.080) after ≥ 12 months of an intensive therapy program on an MDI regimen
were crossed-over to IPT and followed for at least 12 more months.63 No significant
change in A1C was observed from baseline on MDI to follow-up on IPT. However, due to
the intensive therapy program that was offered while on both MDI or IPT (including
quarterly routine visits, 24-hour access to telephone support, and close phone and fax
contact throughout), the glycaemic control of the subjects was fairly good at baseline on
MDI (mean A1C 0.077 ± 0.015). Given that Bode et al. included subjects with recurrent
severe hypoglycaemia, this may have limited the subjects’ ability to safely further
tighten their glycaemic control on IPT. The baseline incidence of severe hypoglycaemia
on MDI in Bode et al. was high (138 events per 100 patient-years), which is 10-fold
higher than the baseline incidence of severe hypoglycaemia in our IPT cohort (13.6
events per 100 patient-years). This difference in severe hypoglycaemia may explain why
a significant decrease in A1C was observed in our IPT cohort, but not in that of Bode et
al., despite similar glycaemic control at baseline.
Paired Difference in Change in A1C
In the matched analyses, a statistically significant paired difference in change in A1C
from baseline to follow-up between the IPT and control subjects was not seen in
Analysis 1. Possible reasons for why Analysis 1 did not show a significant difference are:
there was, in fact, no true difference in the change in A1C between matched pairs of IPT
and control subjects; the greater proportion of missing follow-up A1C values in the
control cohort (47.1%) than in the IPT cohort (19.0%) masked the presence of a
significant difference in the change in A1C; or the differences in baseline characteristics
between those with vs. without missing follow-up A1C values influenced the ability to
detect a significant paired difference in change in A1C. For example, IPT subjects with
missing follow-up A1C values had lower BMI and lower TDD than those without missing
values, while control subjects with missing follow-up A1C values had lower TDD and
were less likely to have a private drug plan than those without missing values. As per the
a priori power calculations (Table 3), the small sample size in Analysis 1 (n=74 pairs) was
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less likely to be a reason for the lack of statistical significance (as even a sample size of
n=50 per group would have been powered to detect a difference as small as 0.00027, or
0.027%, between groups).
However, a statistically significant mean paired difference in change in A1C between
matched pairs of IPT and control subjects of -0.003 (or -0.3%) was seen in Analysis 2. The
definition of a clinically meaningful change in A1C may be somewhat subjective, and to
our knowledge, no studies have examined what constitutes a clinically meaningful
difference in change in A1C (i.e. the clinically significant difference of a difference), but
we believe that our observed paired difference in change in A1C is clinically significant. A
2009 report by the Canadian Agency for Drugs and Technologies in Health90 noted that
data on the minimally clinically important difference (MCID) in A1C for patients with
T1DM is lacking, but prior studies91,92 comparing the effect of different types of insulin in
lowering A1C in patients with T1DM have used a change in A1C of 0.3% as the MCID in
power analyses. In addition, in their 2008 Guidance for Industry,93 the US Food and Drug
Administration also defined a “clinically meaningful reduction” in A1C as 0.3%.
Moreover, given that this mean paired difference in change in A1C of -0.3% between the
IPT and control cohorts was seen in the context of fairly good baseline glycaemic control
and was also accompanied by a decrease in the incidence of severe hypoglycaemia in
the IPT cohort only further underscores the clinical significance of the results.
The only previous observational study to report the difference in change in A1C from
baseline to follow-up between matched IPT and control subjects was Carlsson et al.77 In
their study, they found an unadjusted difference between groups for change in A1C
from baseline to follow-up at 1 year of -0.00507, which is similar to (though slightly
greater than) what we observed in our study. However, they also performed analysis of
covariance adjusting for the baseline A1C, and the adjusted difference between groups
at 1 year was -0.0042 (Table 14). We did not do an adjusted analysis in our study for the
purpose of this thesis, but an adjusted analysis using multivariable regression to account
for potential confounding factors is planned.
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Proportion with Optimal A1C
a) Comparison of Proportions at Baseline vs. at Follow-Up in each cohort
Optimal glycaemic control is a key component in the management of T1DM. According
to the 2013 CDA Clinical Practice Guidelines, the target A1C should be ≤ 0.070 for most
patients with T1DM.2 However, it is also recommended that the target A1C level may be
less strict (i.e. 0.071 - 0.085) in the presence of risk factors that make it unsafe to
achieve tight glycaemic control (i.e. recurrent severe hypoglycaemia, hypoglycaemia
unawareness, severe coronary artery disease, multiple comorbidities) or other situations
in which the potential benefits of tight glycaemic control may not be outweighed by its
risks (i.e. limited life expectancy, high level of functional dependency).2
In our study, the proportion of subjects with an A1C of ≤ 0.070 increased from baseline
to follow-up in the IPT cohort in both analyses (Analysis 1: from 27.0% to 33.3%, Analysis
2: from 25.8% to 32.1%), but these increases were not statistically significant. In the
control cohort, the proportion of subjects with an A1C of ≤ 0.070 increased from
baseline to follow-up only in Analysis 1 (from 22.8% to 26.1%), but this was also not
statistically significant. However, the proportions of IPT subjects with an A1C ≤ 0.073 or
≤ 0.075 did significantly increase from baseline to follow-up (in both Analysis 1 and 2),
yet this was not seen in control subjects. Taken together, this suggests that IPT may help
improve glycaemic control to a certain level, but that there may be a threshold below
which it is difficult to further improve glycaemic control—for example, due to limitations
from hypoglycaemia. Once a patient has reached target optimal glycaemic control (i.e. ≤
0.070) it may be difficult to further lower the A1C, regardless of the method of insulin
delivery. This likely reflects the larger problem of failure to recreate true physiological
insulin delivery in patients with longstanding T1DM.
Mecklenburg et al.61 examined the proportions of subjects with a “normal” A1C at
baseline and while on IPT. In contrast to our study, the proportion of subjects that
achieved a target (i.e. normal) A1C was statistically significantly higher during the first
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year on IPT (26%, n=33) than that at baseline (9%, n=11) (p=0.0001). However, in
Mecklenburg et al.,61 the A1C was “…calculated as a percentage of the mean in a normal
population and converted to the comparable absolute values in our present assay….”
and the normal range of their assay was 0.0045 - 0.0080 (4.5-8.0%). Thus, the threshold
for their target A1C was higher than what was defined as “optimal” in our study.
Furthermore, 8 of the 33 subjects in their study who achieved the target A1C during the
first year on IPT were pregnant, while pregnancy was an exclusion in our study.
Reda et al.69 also compared the proportions of subjects achieving an A1C ≤ 0.070 preand post-IPT start in their study of 105 subjects. In contrast to our study, they found that
a higher proportion of subjects achieved an A1C ≤ 0.070 after IPT start (17.1%, n=18)
compared to before the IPT start (8.6%, n=9). However, they followed subjects up to 6
years after initiation of IPT, but did not specify at what time point after IPT start the
subjects achieved the target A1C. Similarly, Sudhakaran et al.72 showed an increase in
the proportion of subjects achieving an A1C <0.070 on IPT compared to pre-IPT (from 0%
to 17.6%). However, their number of subjects with T1DM was small (n=17). Marmolin et
al.75 also showed an increase in the proportion of subjects who attained an A1C ≤ 0.070
on IPT compared to pre-IPT, from 13% (n=8) to 24% (n=14). In none of these 3 studies
was it stated whether the increase in proportion of IPT users achieving their target A1C
was statistically significant.69,72,75
b) Comparison of Proportions at Follow-Up between IPT vs. Control Cohorts
Since both the IPT and control cohorts had comparable glycaemic control at baseline,
the proportion of subjects who achieved an optimal A1C value at follow-up was
compared between the IPT and control cohorts. In both Analysis 1 and 2, there was a
higher proportion of subjects with an A1C ≤ 0.070 at follow-up in the IPT cohort than in
the control cohort, though only Analysis 2 showed that this difference was statistically
significant. The differing results between Analysis 1 and 2 may again be a function of
sample size, as Analysis 1 included only 74 pairs, while Analysis 2 included almost double
the sample size. (Other potential reasons for the differing results are as stated
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previously above). No prior study compared this proportion at follow-up between an IPT
and control cohort.
5.2.4 Adverse Events
In our study, there were no episodes of DKA at baseline or at follow-up in either cohort.
This is similar to 2 prior retrospective cohort studies, where the incidence of DKA was
negligible in subjects pre- or post-IPT start. 67,72 Several other studies did observe
episodes of DKA but did not note any significant change in the incidence of DKA before
or after IPT use.63,70 Reda et al. reported an incidence of 20 episodes per 100 patientyears in the year prior to IPT start and an incidence of 5 episodes per 100 patient-years
during IPT use, but it was not stated whether this was a statistically significant
decrease.69
In our study, there was no significant difference in the baseline incidence of severe
hypoglycaemia between cohorts, but after 1 year post-IPT/t=0, the IPT cohort had a
significantly lower incidence of severe hypoglycaemia compared to the control cohort.
Other studies have also shown a decrease in the incidence of severe hypoglycaemia with
the initiation of IPT use.63,65,67,69-72 Bode et al. reported a decrease in incidence from 138
events per 100 patient-years while on MDI to 22 events per 100 patient-years while on
IPT63. However, this study was conducted specifically in subjects with recurrent severe
hypoglycaemia, which is why the baseline incidence was so high. Similarly, the other
studies65,67,69-72,75 which showed a significant decrease in incidence of severe
hypoglycaemia with IPT use all had higher incidences at baseline than our study—we
observed an incidence of only 13.6 events per 100 patient-years (IPT cohort) and 13.0
events per 100 patient-years (control cohort) at baseline. This compares to the other 6
studies that had baseline incidences of severe hypoglycaemia at least 2-fold greater than
ours. The low baseline incidence of severe hypoglycaemia seen in our subjects is likely
related to the amount of missing adverse event data in both cohorts. In turn, this likely
contributed to our limited ability to detect any differences from baseline to follow-up
within each cohort, and between cohorts.
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5.2.5 Subgroup Analysis
In our study, subgroup analysis showed that IPT subjects with a baseline A1C ≥ 0.081 had
a mean change in A1C of -0.007 from baseline to follow-up, while IPT subjects with a
baseline A1C 0.071 to 0.080 showed no change, and those with a baseline A1C ≤ 0.070
had a mean 0.004 increase in A1C from baseline to follow-up. In the control cohort,
subjects with a baseline A1C ≤ 0.070 also had an increase in A1C from baseline to followup (mean 0.003 to 0.004 increase), but no significant change in A1C was seen in the
control subjects with a baseline A1C 0.071 to 0.080 or ≥ 0.081. Of note, severe
hypoglycaemia was not the reason for why the subgroup with baseline A1C ≤ 0.070 in
both cohorts showed a significant increase in A1C from baseline to follow-up. In fact, the
majority of severe hypoglycaemic episodes at baseline were seen in the subgroup with
baseline A1C ≥ 0.081 in both cohorts—82.3% (n=14) in the IPT cohort and 66.7% (n=10)
in the control cohort. However, even though the highest baseline severe hypoglycaemia
incidence was in the subgroup with baseline A1C ≥ 0.081 in both cohorts, this subgroup
in the IPT cohort was still able to show a significant reduction in A1C at follow-up, yet
this subgroup in the control cohort was not.
Our results are similar to other studies which showed a differential effect of IPT use on
glycaemic control depending on baseline A1C.63,67,71 Bode et al.63 demonstrated that
those with a baseline A1C ≥ 0.080 had a significant decrease in A1C with IPT use,
whereas those with a baseline A1C < 0.080 did not have any change in A1C with IPT use.
Lepore et al.67 found that those subjects with a baseline A1C > 0.100 had a greater A1C
reduction (-0.015 ± 0.006) with IPT use vs. those with a baseline A1C < 0.080 (-0.006 ±
0.005). Riveline et al.71 also showed a significant (-0.090) improvement in A1C in subjects
with a baseline A1C ≥ 0.090. However, Giménez et al.70 did not find any difference in
glycaemic control in subgroups of subjects divided by baseline A1C ≤ 0.070 or > 0.070,
though given that the mean baseline A1C in their study was 0.079 ± 0.013, the subgroup
with baseline A1C > 0.070 likely had too few numbers to show a difference in subgroup
analysis.
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5.3 Use of WebDR as a Researchable Database
WebDR was a convenient tool which was used to: a) identify all patients with T1DM
followed by the Diabetes Clinics at SJHC, b) assemble a cohort of IPT users and c)
construct a cohort of non-IPT users from which we could select matched controls. This
was the first use of WebDR for research, and the process allowed us to identify both its
strengths and weaknesses as a researchable database.
5.3.1 Identification of Insulin Pump Therapy Cohort and Matched Controls
There are no data fields in WebDR to specifically identify ADP-funded adult IPT users.
Instead, adults with T1DM on IPT were identified via a WebDR query of medication lists
for insulin pump-compatible insulins and insulin doses, and review of their physician
paper chart was performed to confirm ADP coverage. However, to ensure that all
eligible IPT users followed by the Diabetes Clinics at SJHC were identified, IPT use was
also independently verified by comparison to the list of adults started on IPT maintained
by the St. Joseph’s Hospital DEC. Comparing those IPT users identified by WebDR to
those identified by the DEC list showed a 46% concordance between the two data
sources (i.e. of the 229 IPT users identified by WebDR, only 105 were also identified by
the DEC list, while the other 124 were not identified by the DEC list). An additional 119
IPT users on the DEC list were not identified by WebDR. Possible reasons for why
patients were listed as IPT users on WebDR but not on the DEC list are: IPT use was
initiated at another DEC (instead of the St. Joseph’s Hospital DEC); IPT was started when
the patient was under the care of the pediatric program; the patient was on IPT but not
funded by the ADP; or IPT was started prior to September 2008 or after August 2011 and
the IPT start date was not documented on WebDR. Possible reasons for why patients
were listed as IPT users on the DEC list but not on WebDR are: IPT doses were not
entered in the patient’s WebDR record; IPT was started during pregnancy (the Endocrine
Pregnancy Clinic is the only clinic at SJHC that sees adult patients with T1DM but that
does not use WebDR); or the patient was no longer followed by a physician at the
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Diabetes Clinics at SJHC and so they were not entered into WebDR or their WebDR
record was inactivated.
In our study, use of both WebDR and the DEC list allowed us to be confident that all
eligible adults with T1DM on IPT followed by the Diabetes Clinics at SJHC were
identified. However, it does highlight that the use of WebDR as the sole data source to
identify patients who started IPT between September 2008 and August 2011 would not
have captured all IPT users at SJHC during that time. Of note, at the time of manual data
entry of clinical data from physician paper charts (in 2010-2011), documentation of IPT
use was not the highest priority. However, WebDR has now been in routine clinical use
for over 2 years with ongoing updates of patient records at each clinic visit (including
medication lists). We expect that the accuracy of WebDR in identifying IPT users will
have improved, and thus may be used in future studies involving patients on IPT. To
confirm this, a paper chart review of all adult patients with T1DM followed by the
Diabetes Clinics at SJHC is planned, with cross-reference to WebDR to ensure electronic
documentation of IPT use and ADP coverage.
5.3.2 Validation of A1C Dates and Values
Validation of the baseline and follow-up A1C levels and dates was performed. It showed
that WebDR had fair to good (69.4% to 80.6%) accuracy for these variables. Of note,
there were no instances where the WebDR value was incorrect compared to the
reference standard, but rather, the inaccuracy observed was due to missing values in
WebDR. This is related to our study data collection period and the protocol for manual
data entry for data from physician paper charts that was performed in 2010-2011. Given
that the ADP started in September 2008, we required A1C values as early as March
2007. However, when manual data entry was performed, for most physician charts, only
the most recent A1C few values would be entered (and the number of values could
range depending on the data entry clerk).
The accuracy of historical A1C data of our study cohort should now be improved
compared to when our validation was performed, since missing data was entered into
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WebDR at the time of data extraction. As well, WebDR data from 2011 onwards will
likely also be more accurate than what we observed in our validation, given that WebDR
is now being used routinely for clinic visits at almost all of the Diabetes Clinics at SJHC.
The use of WebDR in this study allowed us the opportunity to assess the accuracy of the
glycaemic control data within WebDR, and will help improve its accuracy for use in
future research studies.

5.4 Study Strengths
This study is one of only a few observational cohort studies that has evaluated the effect
of IPT on glycaemic control in a large cohort of adults with T1DM on IPT as compared to
a control cohort of adults with T1DM not on IPT in a “real-world” setting.
In addition, this study is the largest descriptive cohort of adults with T1DM on IPT in
Canada to date. It is also the only study to describe a population of IPT users who are
funded by the Ontario MOHLTC ADP, which has provided IPT funding for adults with
T1DM for the past 5 years. The subjects in our study were all followed by the Diabetes
Clinics of SJHC, a major tertiary care centre with a large geographic catchment area in
Southwestern Ontario, and thus they are likely representative of adults with T1DM both
provincially and nationwide. We judge that our cohort can be used in future studies
evaluating the impact of ADP-funded IPT on adults with T1DM in Ontario. This should
provide valuable information to health policy makers in at least Ontario, if not across
Canada, where funding programs for adults using IPT are varied, or may not exist at all.
Another strength is in the design and analysis of our study. We used 1:1 matching in the
selection of our control cohort and purposefully chose change in A1C as our primary
outcome in an attempt to control for bias due to confounding by 3 important factors:
baseline A1C, age, and duration of T1DM. Prior observational studies67,68,71, 94,95 and
meta-analyses of before-after studies and/or RCTs5,6 have shown that the baseline A1C
is one of the most (if not the most) important factor predictive of improved glycaemic
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control on IPT. Other observational studies have also found that age 67,94-96 and duration
of T1DM95 are related to glycaemic control on IPT.

5.5 Study Limitations
Our study had several limitations. As a retrospective observational study, it was limited
to the data available on WebDR and in the physician paper charts. This reduced our
ability to control for known confounding factors. Despite ensuring that the cohorts were
well-matched for age and duration of T1DM, it is possible that other differences
between the IPT and control cohorts may have contributed to the results seen. We also
attempted to control for differences in baseline A1C by selecting the change in A1C as
our primary outcome, but other potentially important factors exist that could confound
the association between IPT use and glycaemic control.
For example, the greater decrease in A1C seen in the IPT cohort compared to the control
cohort could be due not to IPT per se, but rather to the intensive training and education
that is required prior to initiation of IPT. Further, the patients who are willing to go on
IPT may be inherently more motivated to manage their T1DM in comparison to those
who do not. However, our study does reflect “real-world” conditions in which there are
patients with a wide range of ability for self-management of their T1DM, and in which
some choose to pursue IPT and others do not.
Other factors shown to have been associated with improved glycaemic control on IPT
include blood glucose variability while on an MDI regimen68,76 and the use of a bolus
dose calculator for at least 50% of boluses.97 As data on these factors were not collected
routinely in WebDR or in physician paper charts, we were not able to include these
variables in our study.
Confounding by indication may also be a limitation in our study, as we did not collect
information on the indication for IPT use. It is possible that those patients who were
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started on IPT were recommended to do so by their physicians if their glycaemic control
was persistently suboptimal on MDI, as compared to those patients who were
maintained on MDI, and subsequently be more motivated to improve their glycaemic
control. However, it is somewhat reassuring that the mean A1C in the IPT and control
cohorts was similar at baseline, which would not be expected if the main indication for
IPT in our IPT cohort was suboptimal glycaemic control.
We did measure other clinical variables at baseline that have been shown to be
associated with glycaemic control in adults with T1DM (higher income or educational
status98 and frequency of CBG monitoring99) and in those with T1DM specifically on an
MDI regimen (BMI and insulin dose)68 or on IPT (frequency of CBG monitoring71 and
presence of complications).95 There was no difference in average household income,
mean BMI, or mean TDD at baseline between the cohorts. The IPT cohort did perform
more CBG monitoring at baseline, which may have contributed to the difference in
glycaemic control seen between the IPT and control cohorts. However, the IPT cohort
had a smaller proportion of subjects with at least 1 glycaemic-responsive complication
(i.e. neuropathy), and a prior study95 found that the presence of complications was
predictive of better glycaemic control on IPT. We did not yet perform an analysis
adjusting for these factors; however, this is planned.
Another limitation of our study was the amount of missing outcome data (follow-up A1C
and adverse events) in both cohorts. To address this, 2 analyses were performed for our
primary outcome—Analysis 1 (no imputation) and Analysis 2 (imputation using LOCF for
the missing follow-up A1C values). The proportion of missing values between the IPT and
control cohorts differed significantly in Analysis 1, but there was no significant difference
between cohorts in Analysis 2. Differences in the proportion of missing follow-up A1C
values may explain why Analysis 1 did not show a statistically significant difference in
the paired difference in A1C change score, while Analysis 2 did show a statistically
significant difference.
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Of note, an important assumption for use of LOCF in our study was that the follow-up,
but missing, A1C did not significantly change from the last available A1C level. In Analysis
2, 18/174 (10.3%) of IPT subjects and 55/174 (31.6%) of control subjects had their
follow-up A1C imputed. However, of these imputed values, a large proportion of them,
in both cohorts (14/18, 77.8% in IPT cohort; 24/55, 43.6% in control cohort) were carried
forward from measurements taken between 8-10 months post IPT start/t=0 (i.e.
relatively close to the pre-specified window for follow-up A1C). We think it improbable
that the A1C changed significantly from 8-10 months until 10.5 months. Furthermore, a
prior study by Cohen et al.78 showed that the greatest A1C reduction while on IPT
occurred in the first 6 months, with significant decreases in A1C persisting up until 3
years. Similarly, Lepore et al.67 showed a significant A1C reduction in patients on IPT
within 3 months that persisted until 2 years. Together, this supports our use of LOCF to
impute follow-up A1C values prior to 1 year in our study.
Another limitation in our study is selection bias and its effect on the generalizability of
our results. Since we excluded adults with < 1 year duration of T1DM, IPT patients with <
1 year of IPT use, and pregnant women, our results may not be generalizable to these
populations.
Another potential source of selection bias was the exclusion of patients who did not
have a post-IPT start/t=0 follow-up A1C documented, and those no longer followed (i.e.
with an inactive WebDR record), because they did not return to the Diabetes Clinics for
follow-up. These patients may represent a less motivated population whose glycaemic
control may have worsened during follow-up. In our study, only 1 IPT patient did not
have a follow-up A1C. This is not unexpected, as at least 2 A1C measurements per year
are required for renewal of ADP funding so this ensures that patients return for followup to the Diabetes Clinics. However, 10 control patients with baseline A1C values
available were not selected due to not having a follow-up A1C (either not documented
in WebDR/physician paper chart, or else were no longer followed/inactive record), so
given the higher number of control patients excluded for this reason, there is a concern
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that the control subjects in our study are a selected sample of more motivated patients.
However, if this was the case, it would bias the results toward the null, as the difference
in A1C change score between the IPT and control cohorts would be smaller. However,
given that we did observe a significant difference (in Analysis 2), then it may be inferred
that, had it been possible to include those control subjects excluded for no follow-up
A1C, the difference in A1C change score would have been even larger than what was
observed.

5.6 Future Directions
The results of this study provide evidence to support a beneficial effect of IPT use in
improving glycaemic control in adults with T1DM. We used matching in the design and
analysis to help limit bias due to confounding by age and duration of T1DM, and selected
the change in A1C as our primary outcome to take baseline A1C into account. However,
this study did not use multivariable analysis to adjust for other potential confounding
variables, such as the differences in baseline characteristics seen between the control
and IPT cohorts. Therefore, the next step will be to perform multiple linear regression
analyses to adjust for these baseline differences between the cohorts to obtain a
potentially less-confounded estimate of the association between IPT and glycaemic
control in adults with T1DM.
This study was the first to characterize patients on IPT who are funded by the Ontario
MOHLTC ADP. Future planned studies building on these results include a validation study
with our IPT cohort to validate the Ontario-wide data of all adults on ADP-funded IPT,
and a health care utilization study. We plan to link our cohort data to provincial
healthcare administrative databases to examine the effect of IPT use on important
diabetes-related health care utilization outcomes (i.e. physician outpatient visits, eye
examinations, diabetes-related emergency room visits and hospitalizations).
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Data from our IPT cohort may also be used in a future cost-effectiveness analysis of IPT
therapy in Ontario. A prior health economic comparison study100 in 2009 showed that
IPT may be cost-effective as compared to MDI in adults with T1DM in Canada, but the
study used a theoretical sample with demographic and clinical characteristics based on
those from subjects in the DCCT.26 However, it would be interesting to determine
whether similar results would be obtained if the analysis was done using data from our
real-world IPT cohort.
Lastly, this study was the first to use WebDR, the EMR system of the Diabetes Clinics at
SJHC, for clinical research, and this was the first step in establishing its utility as a
comprehensive researchable database for use in the future to examine other important
clinical research questions in patients with diabetes.
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5.7 Conclusions
Prior meta-analyses of RCTs have shown that IPT can cause a small but significant
improvement in glycaemic control as compared to an MDI regimen. However, there is
more limited evidence for the benefits of IPT in improving glycaemic control and adverse
events under “real-world” conditions, and no studies have been performed in Canada.
Ontario was the first province in Canada to implement a government funding program
supporting the use of IPT in adults, and the program has been in place for 5 years. This
study is the first to characterize a population of ADP-funded IPT users, and to assess the
clinical impact of this funding program in adults. Our findings suggest that ADP-funded
IPT is associated with a clinically relevant improvement in glycaemic control and a
significant decrease in severe hypoglycaemia in adults with T1DM as compared to a
matched control population. This is consistent with findings from prior RCTs, and
provides “real-world” evidence in support of the clinical benefits afforded by the
MOHLTC ADP funding for IPT in Ontario. The results of this study should help inform
health policy makers in Ontario, and encourage continued government support of IPT in
adults with T1DM.
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Appendices

Appendix A – Summary of Existing Funding Programs for Insulin Pump Therapy in Canada

YUKON, NORTHWEST TERRITORIES,
NUNAVUT
(considered on individual basis under
Non-Insured Health Benefits Plan)

BRITISH COLUMBIA
Children ≤ 18 yrs

ALBERTA
All ages

MANITOBA
Children < 18 yrs

SASKATCHEWAN
Youth ≤ 25 yrs
(pump & supplies age ≤ 17
pump only age 18-25)

NEWFOUNDLAND &
LABRADOR
Youth ≤ 25 yrs
ONTARIO
Pediatric program:
≤ 18 yrs
Adult program:
≥ 19 yrs

QUEBEC
Children ≤ 18 yrs

*
NEW
BRUNSWICK
Children ≤ 18 yrs

* Prince Edward Island has no current coverage

NOVA SCOTIA
Youth ≤ 24 yrs
(pump & supplies age ≤ 18
pump only age 19-24)
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Appendix B – Adult Assistive Devices Program Insulin Pump Therapy Clinics in
the Ontario South West Local Health Integration Network

London
Owen Sound, Stratford, St. Thomas, Woodstock
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Appendix C – Assistive Devices Program – Adult Eligibility Criteria for Initial
Application and for Yearly Renewal

Initial Application
1. Applicant has Type 1 diabetes
2. Applicant has demonstrated experience with a basal/bolus insulin regimen for at
least one year
3. Applicant demonstrates the ability to self-assess and take action based on blood
glucose results by: carbohydrate counting, correction bolus & sick day
management
4. Applicant demonstrates a commitment to long-term diabetes follow-up through
regular assessments by diabetes educators and physicians at least 3 times a year
or as deemed appropriate by the diabetes team
5. Applicant has participated in a pre-assessment for insulin pump therapy
according to ADP requirements
Yearly Renewal
1. Applicant continues to demonstrate an ongoing commitment to blood glucose
monitoring a minimum of four times daily
2. Applicant demonstrates the ability to self-assess and take action based on blood
glucose results by: carbohydrate counting, correction bolus & sick day
management
3. Applicant has demonstrated that they have benefited from pump therapy
through one of the following results:
a. Improved quality of life
b. Improved A1C results
c. Reduction in the number of hypoglycaemic events
d. Reduction in the number of diabetic ketoacidosis episodes
e. Improved management of the “dawn phenomenon”
4. Applicant demonstrates a commitment to long-term diabetes follow-up through
regular assessments by diabetes educators and physicians at intervals deemed
appropriate by the ADP Registered Adult Diabetes Program
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Appendix D – Assistive Devices Program – Adult Application Form
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Appendix E – Assistive Devices Program – Adult Renewal Form
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Appendix F – Western University Health Sciences Research Ethics Board Approval
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Appendix G – Western University Health Sciences Research Ethics Board Revision
Approval
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Appendix H – Screenshot
Screenshots of WebDR
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Appendix I – Validation of WebDR Data
The accuracy of WebDR was assessed as compared to the physician paper chart, which
was used as the reference standard for comparison. A computer-generated random
sample of 36 patient records (i.e. 10% of the total sample size) was selected for the
validation. Four variables were validated for accuracy: baseline (i.e. pre-IPT start/t=0)
A1C value, baseline A1C date, follow-up (i.e. post-IPT start/t=0) A1C value, and follow-up
A1C date. If the WebDR value matched the physician paper chart value, it was coded as
a “match”, but if the WebDR value and the physician paper chart value did not match, it
was coded as “no match”. If there was no WebDR value recorded but a value was
present in the physician paper chart, it was coded as “not recorded”.
The results of the validation are presented below:

Variable

Match (%)

No Match (%)

Not Recorded (%)

Baseline A1C value

25 (69.4%)

0 (0%)

11 (30.6%)

Baseline A1C date

25 (69.4%)

0 (0%)

11 (30.6%)

Follow-Up A1C value

29 (80.6%)

0 (0%)

7 (19.4%)

Follow-Up A1C date

28 (77.8%)

0 (0%)

8 (22.2%)

Therefore, the accuracy of WebDR for the baseline and follow-up A1C levels and dates in
our study could be considered fair to good, with accuracy ranging from 69.4% - 80.6%.
The inaccuracy present was due to missing values in WebDR, as opposed to incorrect
values in WebDR.

Appendix J – Baseline Characteristics of those with Missing vs. Non-Missing Follow-Up A1C Values – Insulin Pump Therapy Cohort
Analysis 1
IPT Non-Missing

IPT Missing
n

Age (years)
Duration of T1DM (years)
Gender (Male) – n (%)
Private Drug Plan - n (%)
City (London) - n (%)
Physician (Endocrinologist) – n (%)
Average Yearly Household Income
Baseline A1C
*
Optimal baseline A1C – n (%)
Current smoking – n (%)
At least 1 complication – n (%)
§
At least 1 glycaemic-responsive
complication – n (%)
Complications – n (%)
CVD
CAD
PVD
Retinopathy
Nephropathy
Neuropathy
2

Baseline BMI (kg/m )
Baseline TDD (units)
Baseline # CBG/day
Baseline # injections/day
*

45.4 ± 12.3
25.2 ± 12.8
62 (44.0)
9 (6.4)
63 (44.7)
137 (97.2)
$70,976 ± $12,897
0.077 ± 0.010
38 (27.0)
7 (5.0)
49 (34.8)

Analysis 2

141

p-value

IPT Non-Missing

n
43.3 ± 14.7
25.2 ± 14.8
18 (54.6)
3 (9.1)
17 (51.5)
32 (97.0)
$70,695 ± $12,845
0.079 ±0.013
6 (18.2)
0 (0.0)
11 (33.3)

†

33

IPT Missing
n

0.465
†
0.984
‡
0.273
**
0.701
‡
0.478
**
1.000
†
0.911
†
0.562
‡
0.297
**
0.349
‡
0.877
‡

45.4 ± 12.8
25.2 ± 13.2
74 (46.5)
10 (6.3)
72(45.3)
155 (97.5)
$70,869 ± $12,662
0.078 ± 0.011
41 (25.8)
7 (4.4)
55 (34.6)

159

p-value
n

41.0 ± 11.9
25.0 ± 12.9
6 (40.0)
2 (13.3)
8 (53.3)
14 (93.3)
$71,491 ± $15,191
0.077 ± 0.010
3 (20.0)
0 (0.0)
5 (33.3)

†

15

0.194
†
0.952
‡
0.627
**
0.276
‡
0.550
**
0.366
†
0.880
†
0.693
**
0.763
**
1.000
‡
0.992
‡

48 (34.0)

10 (30.3)

0.682

53 (33.3)

5 (33.3)

1.000

0 (0)
4 (2.8)
1 (0.7)
30 (21.3)
18 (12.8)
16 (11.4)
26.8 ± 4.9
54.1 ± 26.6
4.0 ± 0.7
4.2 ± 0.5

0 (0)
2 (6.1)
0 (0)
9 (27.3)
7 (21.2)
3 (9.1)
25.2 ± 3.6
43.8 ± 18.4
4.1 ± 0.9
4.2 ± 0.6

N/A
**
0.319
**
1.000
‡
0.457
**
0.268
**
1.000
†
0.049
†
0.014
†
0.797
†
0.538

0 (0.0)
5 (3.1)
1 (0.6)
34 (21.4)
22 (13.8)
18 (11.3)
26.5 ± 4.7
53.0 ± 26.0
4.0 ± 0.8
4.2 ± 0.6

0 (0.0)
1 (6.7)
0 (0.0)
5 (33.3)
3 (20.0)
1 (6.7)
25.9 ± 4.6
43.6 ± 19.4
4.0 ± 0.8
4.1 ± 0.4

N/A
**
0.423
**
1.000
**
0.331
**
0.456
**
1.000
†
0.664
†
0.110
†
0.907
†
0.585

126
131
130
135

30
30
33
33

142
147
148
153

14
14
15
15

§

Optimal defined as ≤ 0.070; glycaemic-responsive complications defined as retinopathy, nephropathy, neuropathy
IPT, insulin pump therapy; A1C, glycated hemoglobin; T1DM, type 1 diabetes mellitus; CVD, cerebrovascular disease; CAD, coronary artery disease; PVD, peripheral
vascular disease; BMI, body mass index; kg, kilogram, m, meter; TDD, total daily insulin dose; CBG, capillary blood glucose
†
‡
**
Comparisons between missing and non-missing groups using two sample t-test, Chi-square test, or Fisher’s Exact test
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Appendix K – Baseline Characteristics of those with Missing vs. Non-Missing Follow-Up A1C Values – Control Cohort
Analysis 1
Control Missing

Control Non-Missing
n
Age (years)
Duration of T1DM (years)
Gender (Male) – n (%)
Private Drug Plan - n (%)
City (London) - n (%)
Physician (Endocrinologist) – n (%)
Average Yearly Household Income
Baseline A1C
*
Optimal baseline A1C – n (%)
Current smoking – n (%)
At least 1 complication – n (%)
§
At least 1 glycaemic-responsive
complication – n (%)
Complications – n (%)
CVD
CAD
PVD
Retinopathy
Nephropathy
Neuropathy
2

Baseline BMI (kg/m )
Baseline TDD (units)
Baseline # CBG/day
Baseline # injections/day
*

45.7 ± 14.0
26.8 ± 12.9
52 (56.5)
21 (22.8)
47 (51.1)
85 (92.4)
$71,909 ± $13,993
0.078 ± 0.013
21 (22.8)
15 (16.3)
45 (48.9)

Analysis 2

92

p-value

44.9 ± 12.3
23.4 ± 13.3
45 (54.9)
9 (11.0)
43 (52.4)
74 (90.2)
$68,979 ± $13,806
0.078 ± 0.012
22 (26.8)
18 (22.0)
33 (40.2)

n
†

82

0.675
†
0.092
‡
0.828
‡
0.039
‡
0.859
‡
0.614
†
0.167
†
0.933
‡
0.541
‡
0.343
‡
0.251

148

44.6 ± 11.8
24.2 ± 13.4
13 (50.0)
4 (15.4)
13 (50.0)
23 (88.5)
$71,285 ± $14,480
0.075 ± 0.010
9 (34.6)
7 (26.9)
9 (34.6)

†

26

0.748
†
0.693
‡
0.522
**
1.000
‡
0.849
**
0.473
†
0.773
†
0.078
‡
0.204
**
0.281
‡
0.256

67 (45.3)

9 (34.6)

0.312

**

2 (1.4)
6 (4.1)
0 (0)
47 (31.8)
33 (22.3)
27 (18.2)
27.1 ± 5.3
59.2 ± 35.5
3.7 ± 0.9
4.2 ± 0.7

0 (0)
0 (0)
0 (0)
4 (15.4)
4 (15.4)
6 (23.1)
28.1 ± 6.2
51.8 ± 20.6
3.7 ± 0.6
4.2 ± 0.9

1.000
**
0.593
N/A
‡
0.091
‡
0.427
**
0.590
†
0.453
†
0.147
†
0.712
†
0.702

33 (40.2)

0.389

1 (1.1)
4 (4.4)
0 (0)
29 (31.5)
18 (19.6)
18 (19.6)
27.4 ± 5.4
62.9 ± 39.4
3.6 ± 0.9
4.2 ± 0.6

1 (1.2)
2 (2.4)
0 (0)
22 (26.8)
19 (23.2)
15 (18.3)
27.0 ± 5.6
52.8 ± 25.4
3.9 ± 0.8
4.2 ± 0.8

1.000
**
0.685
N/A
‡
0.497
‡
0.562
‡
0.831
†
0.660
†
0.048
†
0.089
†
0.859

70
81
74
80

45.4 ± 13.5
25.4 ± 13.1
84 (56.8)
26 (17.6)
77 (52.0)
136 (91.9)
$70,396 ± $13,892
0.079 ± 0.013
34 (23.0)
26 (17.6)
69 (46.6)

p-value
n

‡

43 (46.7)

79
89
84
88

Control Missing

Control Non-Missing

n

126
144
136
142

‡

**

23
26
22
26

§

Optimal defined as ≤ 0.070, glycaemic-responsive complications defined as retinopathy, nephropathy, neuropathy
A1C, glycated hemoglobin; T1DM, type 1 diabetes mellitus; CVD, cerebrovascular disease; CAD, coronary artery disease; PVD, peripheral vascular disease; BMI, body
mass index; kg, kilogram, m, meter; TDD, total daily insulin dose; CBG, capillary blood glucose
†
‡
**
Comparisons between missing and non-missing groups using two sample t-test, Chi-square test, or Fisher’s Exact test
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